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Linear ubiquitination is one of the key post-translational modifications that regulate 
immune signalling pathways and cell death. The only known enzyme complex 
capable of forming linear ubiquitin chains de novo is the linear ubiquitin chain 
assembly complex (LUBAC), and its catalytic core component is HOIP. To 
understand the underlying mechanisms of liver inflammation and associated 
carcinogenesis, the physiological role of LUBAC in the liver parenchyma was 
investigated. Here I report that HOIP deficiency in liver parenchymal cells triggered 
spontaneous cell death and inflammation in murine livers at early stages and 
tumourigenesis later in life. HOIP-deficient livers displayed increased cell death, 
including apoptosis, regeneration and immune cell infiltration. TNF-induced NF-κB 
activation was attenuated in HOIP-deficient primary hepatocytes and they were more 
susceptible to TNF-induced cell death independently of their impaired gene- 
activatory capacity. Unexpectedly, however, liver damage observed in HOIP-
deficient livers was TNFR1-independent as co-deletion of TNFR1 did not ameliorate 
cell death in HOIP-deficient livers whilst mitigating their inflammation. In accordance 
with increased cell death, HOIP-deficient hepatocytes displayed enhanced formation 
of a death-inducing signalling complex containing FADD, RIPK1, caspase-8 and c-
FLIP. This elevated signalling complex formation in HOIP-deficient hepatocytes was 
independent of lowered gene-activatory capacity and the presence of TNFR1. 
Moreover, combined ablation of systemic caspase-8 and MLKL completely 
prevented liver damage due to loss of HOIP, whereas MLKL deficiency did not have 
a beneficial effect. This demonstrates a crucial role for aberrant cell death in HOIP-
deficient livers. Collectively, these results identify LUBAC as a previously 
unrecognised tumour suppressor, which acts by restraining TNFR1-independent 
FADD-RIPK1-caspase-8 complex formation and caspase-8-dependent apoptosis, 
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Chapter 1  
1 Introduction 
1.1 Inflammation and liver cancer 
1.1.1 Inflammation 
Inflammation is a physiological response to pathogen infection and tissue damage. 
Inflammation has been classically characterised by five features: heat, pain, redness, 
swelling and loss of function originating from the description in Latin: calor, dolor, 
rubor, tumor and functio laesa (Karin and Clevers, 2016). The inflamed site is 
characterised by vasodilation is mediated by histamine and nitric oxide, which 
increase blood flow and trigger heat sensation and redness. Additionally, an 
adhesive capacity of the blood vessels and vascular permeability are altered, 
allowing leukocyte migration to the infected area, which causes tissue swelling and 
oedema, frequently also imparing local tissue functionality. Lastly, pain can occur 
due to stimulation of nerve endings with inflammatory mediators.  
The innate immune system detects pathogens as the first line of defence (Alberts, 
2002). It recognises pathogens by means of surface-expressed pattern recognition 
receptors, which bind to highly conserved pathogenic structures, pathogen-
associated molecular patterns (PAMPs). When innate immune cells are activated by 
pathogen recognition, they secrete inflammatory mediators, such as cytokines and 
chemokines, which alter the behaviour of other cells to trigger inflammatory 
responses to pathogens. Chemokines can attract other immune cells 
(chemoattraction), and activate them to reinforce the immune response (Janeway 
and Medzhitov, 2002). Cytokines do not facilitate chemotaxis unlike chemokines, but 
they promote transcription of genes which facilitate the inflammatory response. 
An initial step to eliminate incoming pathogens is their engulfment by phagocytes. 
The majority of myeloid cells, including monocytes, macrophages, neutrophils, 
dendritic cells and mast cells are capable of phagocytosing pathogens and attacking 
them with ROS (Aderem and Underhill, 1998). Furthermore, the complement system 
can be activated by immunoglobulin bound to the surface of pathogens or lectin 
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molecules on pathogens themselves to be phagocytosed or lysed (Medzhitov and 
Janeway, 1999).  Upon activiation, the complement system creates a pore-forming 
complex on recognized pathogens to eliminate them. 
NK cells are another innate immune cell type capable of recognising pathogen-
infected cells. NK cells kill target cells by releasing perforin and granzymes upon 
activation, which in turn create a pore in the plasma membrane of infected cells and 
activate caspases thereof, respectively (Vivier et al., 2008).  
Additionally, phagocytes are crucial for relaying signals from the innate immune 
system to the adaptive immune system via antigen presentation. Phagocytosed or 
pinocytosed pathogens are digested in these cells. Pathogen-derived peptides are 
presented to naïve T cells by MHC molecules to activate adaptive immunity 
response. Both antigen presentation and co-stimulation are central for T cell 
activation to enable naïve T cells to proliferate and differentiate into effector, helper 
and regulatory T cells (Janeway et al., 2001).   Peripheral naïve T cells mainly 
consist of CD4 and CD8 positive cell subsets.  CD4+ T cells activated by MHC class 
II-peptide complexes differentiate largely into helper T cells such as TH1, TH2, or 
TH17 and inducible Treg cell subsets. The differentiation of naïve T cells is 
orchestrated by an array of cytokines, chemokines and growth factors produced by 
APCs and surrounding cells. CD8+ T cells, by contrast, are activated by MHC class I-
peptide complexes on APCs. The naïve CD8+ T cells then differentiate into cytotoxic 
T cells that can recognise the foreign antigen peptides presented on MHC class I 
molecules in infected cells. The killing mechanisms of cytotoxic T cells upon target 
recognition are similar to NK cells, again involving granzymes and perforin. 
B cells are triggered upon encountering their antigens from infected cells or APCs 
which bind to their receptor (BCR). B cells can digest antigens intracellularly and 
present them to T cells with corresponding T cell receptors (TCRs) via MHC class II 
molecules. Subsequently activated T cells secrete cytokines that activate B cells to 
elicit antibody production against their antigens. Secreted antibodies bind to antigens, 
allowing recognition and subsequent elimination by cells expressing Fc receptors, 
such as phagocytes and NK cells, to recognise and eliminate those (Janeway et al., 
2001).    
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While activated innate immune cells and T cells produce pro-inflammatory cytokines, 
they also secrete anti-inflammatory mediators, including IL-10 and TGF-β to regulate 
inflammation. In addition, T cells are regulated by co-inhibitory receptors such as 
CTLA-4 and PD-1. Among T cells, Tregs play a crucial role in suppression of 
inflammation.  Mutation in the FoxP3 gene, which is a transcription factor required for 
regulatory T cell induction, is causative for immunodysregulation polyendocrinopathy 
enteropathy X-linked syndrome (IPEX), which is an autoimmune disease (van der 
Vliet and Nieuwenhuis, 2007). This evidence indicates that suppressive immune 
signalling is essential to control inflammation. 
1.1.2 Inflammation and cancer 
It has been argued that inflammation is strongly associated with cancer. Research 
showed that infections are linked to 15-20% of all cancer-related deaths (Balkwill and 
Mantovani, 2001). For instance, Helicobacter pylori infection is a major cause of 
stomach cancers. Also, patients with chronic inflammation carry a higher risk of 
tumour malignancy (Balkwill and Mantovani, 2001). Accordingly, recent large 
epidemiological studies implicate that non-steroidal anti-inflammatory drugs 
(NSAIDs) could help to circumvent tumour development (Rothwell et al., 2012; Chan 
and Ladabaum, 2015). 
In late 19th century, Rudolf Virchow observed that leukocytes are present in 
neoplastic tissues and suggested a connection between inflammation and cancer 
(Balkwill and Mantovani, 2001). The tumour microenvironment includes leukocytes in 
the tumour-supporting stroma as well as intra-tumour areas. Inflammatory cells and 
mediators participate in tumour growth, progression, metastasis, and 
immunosuppression. The majority of tumour-associated leukocytes are tumour-
associated macrophages (TAM), dendritic cells, and lymphocytes (Mantovani et al., 
2002). Pro-inflammatory cytokines from tumour-infiltrating immune cells and tumour 
cells themselves contribute to tumour progression by causing DNA damage, 
stimulating growth, subverting antitumour immunity, and enhancing invasion 
(Hanahan and Weinberg, 2011).  
On the other hand, the immune system is capable of detecting tumour cells and 
specifically killing them by the action of cytotoxic T cells and NK cells. Interestingly, 
19 
 
tumour cells originating from immunodeficient mice are incapable of colonising and 
growing in syngeneic immunocompetent mice, whilst cancer cells from 
immunocompetent mice are capable of doing so in both hosts. This evidence 
suggested that, in immunocompetent mice, immunogenic cells presenting non-self 
antigens are removed by the immune system so that only less immunogenic cells 
can thereafter survive (Kim et al., 2007). By contrast, since immunodeficient mice fail 
to reject immunogenic pre-cancerous cells, these cells cannot survive 
immunocompetent environment after transplantation (Teng et al., 2008). The 
concept of constant removal of tumourigenic cells is termed cancer 
immunosurveillance, or immunoediting (Dunn et al., 2004; Hanahan and Weinberg, 
2011).  
Thus, developed cancers often evade the destruction by immune cells by being less 
immunogenic or protected from the recognition by cytotoxic T cells (Hanahan and 
Weinberg, 2011). The recent success of clinical immune checkpoint blockade, which  
targets co-inhibitory molecules such as CTLA-4 and PD-1, proves that T cell 
functions in human cancers are indeed impaired by these co-inhibitory molecules 
(Sharma and Allison, 2015).  Ligands of PD-1 can be expressed by stromal cells as 
well as tumour cells to dampen T cell activation. Moreover, the presence of Tregs, 
TH2 and TH17 cells in tumours is suggested to promote subversion of the immune 
system to block antitumour immunity, for example, by skewing TAM to M2 
macrophages, which produce immunosuppressive cytokines IL-10 and TGFβ 
(Mantovani and Allavena, 2015).  
In addition to the response to invading pathogen and regulation on tumour 
development, inflammation also plays a central role in wound healing and tissue 
regeneration (Karin and Clevers, 2016). Upon tissue injury or infection, damaged 
cells release PAMPs and danger-associated molecular patterns (DAMPs), as well as 
ROS. Thus tissue damage activates multiple signalling pathways in the surrounding 
cells via recognition of PAMPs and DAMPs, leading to the production of 
inflammatory mediators. Inflammatory cytokines, in turn, stimulate the growth of stem 
cells and facilitate turn-over of blood vessels and fibroblasts. Also, they can induce 




1.1.3 Liver cancer  
The major types of human primary liver tumour are hepatocellular carcinoma (HCC) 
and cholangiocarcinoma (CCA), where HCC is the most common type of liver cancer.  
HCC is the fifth most common cancer in men and seventh most common in women 
(Marquardt et al., 2015). The leading cause for HCC is hepatotropic virus infection in 
sub-Saharan Africa and Asia, as well as alcohol abuse worldwide. In addition, in 
Western countries, diabetes and obesity are increasingly associated with HCC 
without a history of cirrhosis. HCC is considered to be derived from mature 
hepatocytes, or liver progenitor cells (Marquardt et al., 2015).  
Infection with hepatotropic viruses, notably HBV or HCV, is found in the large 
majority of patients with HCC (El-Serag, 2011). This viral infection causes chronic 
inflammation and subsequent cirrhosis. Some viral proteins are also capable of 
transforming hepatocytes to be pre-tumourigenic by blocking p53 protein, which is a 
tumour suppressor gene crucial for maintaining genomic stability (Wang et al., 1994; 
Ueda et al., 1995). 
The most common frequently mutated oncogene in HCC is CTNNB1 encoding β-
catenin, whilst the most commonly mutated tumour suppressor gene is TP53 which 
encodes p53 protein (Kan et al., 2013). In addition, genetic alterations leading to 
HCC are related to oncogenic networks, including canonical Wnt signalling (eg 
amplifications in FZD6 and RSPO2, mutations in CTNNB1, AXIN1, APC), the JAK-
STAT pathway (eg amplification in IL6R, JAK1 mutation), chromatin modification (eg 
SWI/SNF mutation), apoptotic pathways (eg deletions in TNFRSF10A/B, CASP3) 
and the PI3K-AKT-mTOR pathways (eg PTEN, RPS6KA3 mutations) (Kan et al., 
2013; Marquardt et al., 2015).  
1.1.4 Mouse models of autochthonous hepatocellular carcinoma 
In order to understand the nature of liver cancer development, researchers 
generated several mouse models that can mimic human HCC. The models can be 
classified according to the trigger of tumourigenesis: 1) viral gene transgenics, 2) 
chemicals and 3) gene editing (Heindryckx et al., 2009; Weber et al., 2011). 
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1.1.4.1 Viral protein transgenics 
The most common cause of HCC is viral hepatitis-induced carcinogenesis. In the 
case of HBV infection, the replication of HBV inside human hepatocytes can cause 
transformation of hepatocytes and cell death. 
The replication of HBV requires the function of the HBX, which a viral protein is 
essential for HBV infection. HBX alters cell signalling in multiple aspects to transform 
hepatocytes into pre-tumourigenic cells (Murakami et al., 2001). First, HBX can 
serve as a coactivator of transcription by binding to transcriptional activators, CREB 
and NF-κB (Su et al., 1996). HBX also activates oncogenic signalling such as Src 
and Ras pathways (Doria et al., 1995; Bouchard et al., 2001). Furthermore, HBX 
inhibits the function of p53 protein by direct interaction (Wang et al., 1994; Ueda et 
al., 1995). Ectopic expression of the HBX gene in mice triggers an alteration of 
hepatocytes, resulting in HCC formation at 13 months of age (Kim et al., 1991). 
When combined with the overexpression of the proto-oncogene c-myc, liver 
carcinogenesis by HBX is accelerated by promoting transformation of hepatocytes 
(Teradillos et al., 1997).  
In addition, a transgene of the HBV envelope protein induces hepatocyte cell death 
in mice due to the accumulation of viral surface protein HBsAg in the ER (Chisari et 
al., 1989). Mice transgenic for the HBV envelope protein develop inflammation and 
regenerative hyperplasia, which eventually leads to carcinogenesis at 15 months of 
age (Chisari et al., 1989).  
1.1.4.2 Chemically-induced and diet-induced liver carcinogenesis 
DEN is the most commonly used carcinogen to induce liver cancer in rodents. DEN 
is oxidised and activated in hepatocytes by cytochrome P450 to function as a DNA-
alkylating agent, and it also causes ROS production (Heindryckx et al., 2009). 
Previous research demonstrated that DEN-induced tumours have close gene 
expression signatures to those of HCC patients with poor survival (Lee et al., 2004). 
A single injection of DEN into male mice at 2 weeks of age is sufficient to trigger 
tumourigenesis. Of note, as mice ages, they are more resistant to DEN-induced 
carcinogenesis (Lee et al., 1998). Male mice are more prone to bear DEN-induced 
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tumours as compared to females due to higher MyD88-dependent IL-6 production 
(Naugler et al., 2007).  
Dietary change can be also a model of liver tumourigenesis. For instance, choline-
deficient diet induces severe steatosis in murine livers. Dietary choline deficiency 
combined with a high level of fat intake (CD-HFD) induces steatosis, oxidative stress, 
hepatocyte ballooning and HCC in C57BL/6 mice, whilst HFD alone does not induce 
carcinogenesis (Wolf et al., 2014). CD-HFD-induced steatohepatitis and HCC is 
promoted by CD8+ T cells and NKT cells (Wolf et al., 2014). Moreover, HFD 
treatment combined with DEN injection is another model of steatohepatitis-
associated hepatocarcinogenesis (Park et al., 2010).  
1.1.4.3 Gene deletion and editing 
Mdr2 knockout mice are often employed to mimic inflammation-associated HCC 
formation. Mdr2 belongs to the ABC transporter family and is involved in the 
transport of phospholipids and cholesterol into bile. Mdr2 knockout mice develop 
cholestasis and severe biliary fibrosis prior to carcinogenesis (Popov et al., 2005). 
Defective bile secretion leads to cholangitis and fibrosis, which results in 
tumourigenesis. 
Tyler Jacks and colleagues reported that concomitant deletion of PTEN and p53 in 
hepatocytes, using hydrodynamic injection and CRISPR/Cas9 system, results in 
rapid tumour development (Xue et al., 2014). They also succeeded in introducing 
oncogenic PTEN and β-catenin mutations in the liver with the same method. As 
CRISPR/Cas9 allows multiplexed gene deletion and editing, it is a feasible tool to 
mimic mutagenesis of multiple genes, thereby enabling better modeling of HCC 
found in human patients (Weber et al., 2015). Therefore, in parallel to classical 
methods of tumour initiation and promotion with chemicals, emerging genome editing 




1.2 NF-κB and cell death signalling in liver disease 
1.2.1 NF-κB signalling 
NF-κB is a family of transcription factors that are activated by various immune 
stimulations and induce expression of pro-survival genes, pro-inflammatory 
cytokines and immunoregulatory proteins (Sen and Baltimore, 1986; Oeckinghaus 
and Ghosh, 2009). The NF-κB family consists of five proteins, RelA/p65, RelB, c-Rel, 
NF-κB1/p105 and NF-κB2/p100. These proteins are divided into two classes. Class 1 
NF-κB proteins are p105 and p100, which are initially produced as precursor proteins 
and processed into p50 and p52, respectively, by the ubiquitin-proteasome system 
(Liang et al., 2006). Processing of p105 occurs constitutively whereas that of p50 is 
tightly regulated by phosphorylation. Although p50 and p52 have DNA-binding and 
dimerisation domains, they depend on additional factors for activation of gene 
transcription (Ghosh et al., 1998). These class 2 NF-κB proteins, RelA, RelB and c-
Rel harbour transactivation domains in their C-termini and DNA-binding and 
dimerisation domains in their N-termini. RelA, RelB and c-Rel activate target gene 
transcription by forming homodimers or heterodimers with p50 or p52 (Ghosh et al., 
1998).  
NF-κB activity is tightly regulated and normally suppressed by IκB family proteins. 
IκB proteins contain ankyrin repeats which bind to the DNA-binding and dimerisation 
domain of NF-κB proteins to prevent their activity. The best characterised IκB is IκBα, 
which constitutively binds to the NF-κB-activating heterodimeric RelA-p50 complex 
(Ghosh and Baltimore, 1990). Upon NF-κB-activating stimulation, IκBα is subjected 
to degradation by the ubiquitin-proteasome system, which in turn releases RelA-p50 
to activate gene transcription (Yaron et al., 1998; Fuchs et al., 1999). Also, precursor 
forms of p105 and p100 are considered to be inhibitory as their C-terminal ankyrin 
repeats can serve as a function of IκB proteins. These inhibitory domains of p105 




Figure 1.1 Simplified scheme of canonical and non-canonical NF-κB pathways 
 
The IκB kinase (IKK) complex plays a critical role in activation of NF-κB (Häcker and 
Karin, 2006). The IKK complex initially activates NF-κB signalling by phosphorylating 
IκB proteins. In canonical NF-κB signalling, the IKK complex is comprised of two 
kinases IKK1/IKKα and IKK2/IKKβ and a scaffold protein NEMO/IKKγ (Mercurio et 
al., 1997; Rothwarf et al., 1998; Yamaoka et al., 1998). IKK1 and IKK2 have kinase 
domains in their N-terminus and bind to NEMO via C-terminal NEMO-binding 
domains. In canonical NF-κB signalling, which is activated by stimuli such as TNF, 
IL-1 or LPS, the IKK complex is activated by the recruitment to the corresponding 
receptor complexes. IKK2 is sufficient and essential for the IKK complex to 
phosphorylate IκBα in a NEMO-dependent manner and triggers its proteasomal 
degradation (Oeckinghaus and Ghosh, 2009) (Figure 1.1, left panel).  
In non-canonical NF-κB signalling, which is activated by subsets of TNF superfamily 
receptors including CD40, lymphotoxin beta receptor and BAFFR, NF-κB-inducing 
kinase (NIK) plays a central role in activating NF-κB. Upon receptor oligomerisation, 
NIK is stabilised and phosphorylates IKK1 (Senftleben et al., 2001; Liao et al., 2004). 
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IKK1 homodimer subsequently phosphorylates p100, which results in degradation of 
their inhibitory C-terminal ankyrin repeats by SCFβTrCP ubiquitin ligase complex and 
processing into p52 (Coope et al., 2002; Liang et al., 2006). p52 forms heterodimers 
with RelB to activate target gene transcription (Bonizzi and Karin., 2004) (Figure 1.1, 
right panel). Whilst canonical NF-κB activation is rapid and transient, non-canonical 
NF-κB activation is slower and persistent and exerts specific functions depending on 
cell types and activating receptors (Sun, 2011). 
1.2.2 NF-κB activating modules 
NF-κB is activated upon diverse immune stimulation, such as cytokines (eg TNF and 
IL-1), PAMPs (eg LPS and viral DNA/RNA) and immunomodulatory receptors (eg 
CD40, TCR and BCR). As explained in the previous section, NF-κB activation 
depends on whether IKK is activated. Here I describe how IKK and NF-κB are 
activated by coordinated signalling cascades from representative immune receptors. 
1.2.2.1 TNFR1 signalling 
TNF is a well-studied potent activator of NF-κB signalling. Ligation of TNF to its 
receptor TNFR1 triggers trimerisation of TNFR1. Upon oligomerisation of TNFR1, 
the first proteins recruited to the TNFR1 are TRADD and RIPK1 via homotypic death 
domain (DD) interaction (Hsu et al., 1995; Zheng et al., 2006; Ermolaeva et al., 2008; 
Pobezinskaya et al., 2008). TRADD, in turn, recruits TRAF2/5 via TRAF binding 
domain, which subsequently associates with the E3 ubiquitin ligase cIAP1/2 (Hsu et 
al., 1996; Tsao et al., 2000). cIAP1/2 then ubiquitinate themselves, RIPK1 and other 
components within the TNFR1-associated signalling complex (TNF-RSC) (Ea et al., 
2006; Bertrand et al., 2008; Varfolomeev et al., 2008). Ubiquitination of cIAP1/2 and 
RIPK1 then triggers the recruitment of another E3 ubiquitin ligase complex linear 
ubiquitin chain assembly complex (LUBAC), the TAK1-TAB2-TAB3 complex to 
ubiquitin chains formed in the TNF-RSC (Kanayama et al., 2004; Ea et al., 2006; Haas 
et al., 2009; Vince et al., 2009). LUBAC further ubiquitinates RIPK1, NEMO, TRADD 
and TNFR1 (Gerlach et al., 2011; Draber et al., 2015), thereby stabilising the TNF-
RSC and allowing recruitment of the IKK complex. TAK1 is a kinase which on one 
hand, phosphorylates IKK1/2, leading to activation of NF-κB signalling, and, on the 





Figure 1.2 Schematic representation of TNFR1 signalling 
 
1.2.2.2 IL-1/TLR signalling 
IL-1R and TLRs activate downstream signalling in a similar manner, as they share 
homology in intracellular Toll/IL-1R (TIR) domains for the recruitment of respective 
signalling complexes. Upon binding of the respective ligand, the receptors undergo 
dimerisation and conformational change that allows recruitment of downstream 
signalling components (Akira and Takeda, 2004). MyD88 is one of the first adaptors 
recruited to IL-1R/TLR via TIR domain interaction. MyD88 is universally engaged in 
IL-1R and all TLR signalling except for TLR3 signalling (Kawai and Akira 2010). The 
N-terminal DD of MyD88 serves as an association platform for kinase IRAK1/2/4 
through a homotypic interaction between their DDs. IRAK4 is considered to be the 
most important proximal kinase (O’Neill et al., 2003). IRAK4-mediated IRAK1 
activation leads to interaction with the E3 ligase TRAF6, which in turn ubiquitinates 
itself and IRAK1, allowing the recruitment and activation of the TAK1-TAB2-TAB3 
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complex mediated by the ubiquitin-binding capability of TAB2/3 (Ninomiya-Tsuji et al., 
1999; Ishitani et al, 2003; Kanayama et al., 2004). 
1.2.2.3 NOD2 and RLR signalling 
Other PAMP receptors including NOD2 and RIG-I/MDA5 can also activate canonical 
NF-κB signalling. NOD2 receptors bind to peptidoglycan dipeptide, muramyl 
dipeptide (MDP), (Girardin et al, 2003; Inohara et al, 2003). The NOD2 receptor 
recruits RIPK2, XIAP and cIAP1/2 upon activation and ubiquitination of RIPK2 by 
IAPs leads to the subsequent recruitment of the TAK1-TAB2/3 complex and the IKK 
complex to trigger NF-κB signalling (Inohara et al., 2000; Strober et al., 2006; 
Bertrand et al., 2009). In addition, LUBAC is also engaged in ubiquitination of RIPK2 
to facilitate NF-κB signalling (Damgaard et al., 2012). 
RIG-I and MDA5 are receptors for foreign DNA derived from infectious viruses. Upon 
recognition of cytosolic DNA, they bind to the adaptor protein MAVS on the outer 
mitochondrial membrane, thereby triggering oligomerisation of MAVS (Takeuchi and 
Akira, 2008). Activated MAVS recruits TRAF proteins, which in turn become a 
platform for recruitment of the TAK1-TAB2/3 complex and the IKK complex. 
1.2.2.4 TCR/BCR signalling 
In addition to innate immune signalling pathways, adaptive immune receptors are 
also activators of NF-κB signalling. Upon activation both TCR and BCR recruit the 
CBM complex consisting of CARD11/CARMA1, BCL10 and MALT1 upon 
engagement of receptor-proximal adaptors and kinases (Thorne et al., 2004; Beyeart, 
2014). In the CBM complex, BCL10 is ubiquitinated in Lys63-linked and Met1-linked 
manners by a concerted action of the E3 ligases, cIAP1/2 and LUBAC, respectively 
(Dubois et al., 2014; Yang et al., 2014; Yang et al., 2016). Ubiquitination of BCL10 is 
critical for the recruitment of NEMO by its binding capacity to polyubiquitin, which in 






1.2.2.5 Non-canonical NF-κB activators 
Non-canonical NF-κB activators are members of TNF superfamily receptors, 
including lymphotoxin beta receptor (LTβR), CD40, BAFFR (Häcker and Karin, 2006). 
LTβR is mainly expressed on lymphoid cells and epithelial cells. There are two 
ligands for LTβR: lymphotoxins and LIGHT, cytokines mainly produced by T cells. 
Membrane-anchored LTβ forms heterotrimers with soluble LTα (LTα1β2 and LTα2β1). 
LTβR activates non-canonical NF-κB signalling as well as canonical NF-κB signalling 
(Coope et al, 2002). LTβR signalling is central for lymphoid organogenesis (Sun et 
al., 2012).  CD40 is expressed on APCs and activated B cells, and its ligand CD40L 
is predominantly expressed on activated T cells (Elgueta et al., 2009). CD40 is a vital 
co-stimulatory molecule in the immune synapse formation upon antigen presentation. 
CD40 signalling modulates B-cell functions, such as germinal centre formation and 
isotype class switching (Ma and Clark, 2009).  CD40L-CD40 also elicits activation of 
both canonical and non-canonical NF-κB pathways (Coope et al, 2002). BAFFR is 
exclusively expressed on B cells and is involved in maturation of peripheral B cells 
(Mackay and Schneider, 2009). Unlike CD40, BAFFR specifically activates non-
canonical NF-κB and is hardly capable of activating canonical NF-κB signalling 
(Claudio et al, 2002). BAFFR-mediated activation of non-canonical NF-κB promotes 
B-cell survival via induction of Bcl-2 and Bcl-XL (Mackay and Schneider, 2009). 
These recepetors contain TRAF-binding motif to recruit TRAF3, which leads to the 
subsequent degradation of TRAF2 and TRAF3, which is mediated by cIAP1/2 
(Vallabhapurapu et al, 2008; Zarnegar et al, 2008). Degradation of TRAF2/3 thereby 
leads to stabilisation of NIK (Sun, 2011). 
It is suggested that the non-canonical pathway activation requires de novo synthesis 
of NIK as well as degradation of TRAF2 or TRAF3 (Sun, 2011). Normally, the level of 
NIK protein is maintained at an extremely low level due to its constant degradation 
by the ubiquitin-proteasome system (Liao et al., 2004).  This degradation of NIK is 
orchestrated by TRAF3, TRAF2 and cIAP1/2, with TRAF3 being central to the 
inhibition of NIK (Liao et al., 2004; Vallabhapurapu et al, 2008; Zarnegar et al, 2008). 
TRAF3 is bound to the N-terminus of NIK and targets NIK for constant ubiquitination 
in a Lys48-linked manner by the E3 ubiquitin ligase cIAP1/2. Loss of TRAF2 or 
TRAF3, or degradation of cIAP1/2 by Smac mimetic compounds causes 
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accumulation of NIK and aberrant p100 processing, leading to non-canonical NF-κB 
activation (Vallabhapurapu et al, 2008; Zarnegar et al, 2008).  
1.2.3 Cell death pathways 
1.2.3.1 Apoptosis 
The best characterised programmed cell death is apoptosis, executed by a cascade 
of activated caspases, resulting in DNA fragmentation and cell blebbing. Apoptotic 
pathways were initially investigated in C. elegans employing forward genetic 
methods. Thereby mutants that do not undergo cell death increase cell numbers in 
their bodies (Ellis et al., 1991). Apoptosis is crucial in morphogenesis as well as 
tissue homeostasis. In apoptotic cell death, executioner caspases cleave multiple 
cytoskeletal proteins including actin and nuclear lamins, which leads to the loss of 
cellular structure and blebbing. In addition, they cleave inhibitor of caspase-activated 
DNase (ICAD) to release and activate DNase CAD, resulting in fragmentation of 
nuclear DNA (Fischer et al., 2003). 
There are two classical routes of interconnected apoptotic pathways: the intrinsic 
and the extrinsic pathway (Scaffidi et al., 1998; Jost et al., 2009). The intrinsic 
pathway is mediated by the mitochondria, whereas the extrinsic pathway is triggered 
by receptors for apoptosis-inducing ligands. Intrinsic death pathway is activated by 
cellular stresses such as DNA damage and oxidative stress. Under such stresses, 
activation of pro-apoptotic Bcl-2 family member proteins, Bax and Bak, leads to their 
oligomerisation and insertion to mitochondrial outer membranes, leading to 
mitochondrial outer membrane permeabilisation (MOMP) (Tait and Green, 2013). 
MOMP triggers the release of mitochondrial contents into the cytosol. A key 
mitochondrial protein initiating apoptosis is cytochrome c, which is a component of 
the electron transport chain in the mitochondria. Released cytochrome c binds to 
Apaf-1 and provokes its conformational change, which leads to the formation of a 
heptameric complex of Apaf-1-cytochrome c, referred to as apoptosome (Li et al., 
1997). The apoptosome also contains procaspase-9 which is recruited to Apaf-1 by 
CARD domain interaction between these proteins (Riedl et al., 2007). Dimerisation of 
pro-caspase-9 at the apoptosome results in cleavage and activation of caspase-9. 
Activated caspase-9 subsequently cleaves and activates the executioner caspase-3 
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and -7 (Tait and Green, 2013). In addition to cytochrome c, the mitochondrial 
proteins Smac/Diablo and HtrA2/Omi promote apoptosis execution by inhibiting anti-
apoptotic IAPs, which normally bind to executioner caspases and suppress their 
activation (Jost et al., 2009). 
The extrinsic apoptosis pathway is activated by TNF superfamily receptors, referred 
to as death receptors (DRs), such as TNF-R1, DR3/TRAMP, TRAIL-R1/DR4, TRAIL-
R2/DR5 (in H. sapiens; M. musculus has only one TRAIL-R), CD95/Fas, and DR6 
(Walczak, 2013). In the cases of TRAIL-Rs and CD95, upon ligation by their 
respective ligands, these receptors trimerise (oligomerise) and their intracellular DDs 
recruit FADD as an adaptor protein. In turn, FADD recruits caspase-8 via DED 
interaction and subsequently activates caspase-8 by forming the DISC (Kischkel et 
al., 1995; Boldin et al., 1996; Muzio et al., 1996; Bodmer et al., 2000; Kischkel et al., 
2000; Sprick et al., 2000). Caspase-8 activated at DRs cleaves executioner 
caspases, leading to apoptosis of stimulated cells. Caspase-8 activity is controlled by 
a negative regulator c-FLIP, which harbours DED domains on its N-terminus and a 
caspase-like domain on its C-terminus which does not have proteolytic activity. c-
FLIP forms heterodimers with caspase-8 and hence restricts its apoptotic function 
(Irmler et al., 1997; Oberst et al., 2011; Dillon et al., 2012) (Figure 1.3).  
The extrinsic cell death pathway is connected to the mitochondrial apoptosis 
pathway. The pro-apoptotic BH3-only family protein Bid is cleaved by caspase-8 to 
initiate the mitochondrial pathway. Truncated Bid (tBid) translocates to the 
mitochondria, where it activated Bax and/or Bak to induce MOMP (Wei et al., 2000). 
Whilst the primary function of TNF is to promote gene activation, in certain contexts 
TNF can induce cell death. When the TNF-RSC is not properly assembled or gene 
activation is not optimally executed, a part of the TNF-RSC is released into the 
cytosol, including TRADD and RIPK1, and nucleates a secondary cytosolic complex, 
termed complex II, together with FADD and pro-caspase-8, which results in 
activation of the initiator caspase-8 and subsequent apoptosis (Micheau and 





When the TNF-RSC formation is compromised or caspase-8 is inhibited or lacking in 
cells, TNF executes another type of cell death, termed programmed necrosis or 
necroptosis. This emerging type of cell death was shown to be non-apoptotic and 
caspase-independent (Wang et al., 2005). Despite this interesting finding, a 
physiological role of necroptosis was unclear and questioned for several years. 
Recent studies clarified that viral proteins such as vICA protein of CMV blocks 
caspase-8 when the virus infect cells in order to avoid apoptosis of host cells. 
However, infected cells can still undergo necroptosis (Mocarski, 2015). This 
suggests that cells can execute necroptosis as an alternative cell death mechanism 
when caspases are inhibited. In addition, human biopsies of patients with ischemia-
reperfusion injury and DILI display a sign of necroptosis in biopsies (Linkermann et 
al., 2013, Wang et al., 2014). Thus viral infections and tissue injury may involve 
necroptosis in some cases. 
Mechanistically, necroptosis is orchestrated by the RIP kinases, RIPK1 and RIPK3, 
and the pseudo-kinase MLKL (Sun et al., 2012). When RIPK3 is activated by the 
RHIM domain interaction with RIPK1 and the kinase activity of RIPK1, RIPK3 
autophosphorylates itself and phosphorylates MLKL. Phosphorylation of MLKL, in 
turn, results in a conformational change and translocation of MLKL to the plasma 
membrane (Dondelinger et al., 2014; Cai et al., 2014). Pore-forming MLKL interacts 





Figure 1.3 TNF-induced formation of cell death-inducing complexes. TNF stimulation can trigger 
cell death under certain circumstances. When translation is inhibited or RIPK1 is absent, TNF 
stimulation leads to formation of the TRADD-FADD-caspase-8 complex and activation of caspase-8. 
Absence of cIAPs, NEMO or TAK1 results in RIPK1-FADD-caspase-8 complex formation. c-FLIPL 
restricts activation of caspase-8 and also prevents necroptosis by cleaving RIPK1/3. Formation of 
caspase-8 homodimers causes apoptosis. In the absence or inactivation of caspase-8 or recruitment 
of c-FLIPS, TNF signalling leads to RIPK1-RIPK3-MLKL-mediated necroptosis (Figure modified from 
Conrad et al., 2016). 
 
When caspase-8 is functional, activated caspase-8 dimers inactivate RIPK1 and 
RIPK3 by cleaving them (Figure 1.3). Therefore, the apoptotic pathway prevents the 
activation of necroptosis. (Kaiser et al., 2011; Oberst et al., 2011; Zhang et al., 2011). 
Accordingly, FADD is required for activation of caspase-8 to prevent necroptosis. 
Indeed, FADD deficiency in mice causes RIPK3-dependent necroptosis (Welz et al., 
2011; Bonnet et al., 2011). Moreover, the longer isoform of c-FLIP (c-FLIPL) is a 
suppressor of caspase-8-mediated apoptosis but c-FLIPL allows a partial activation 
of caspase-8 by forming heterodimers with caspase-8, which are able to cleave 
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RIPK1 and RIPK3 to prevent cells from necroptotic death (Oberst et al., 2011) 
(Figure 1.3). By contrast, the shorter isoform of c-FLIP (c-FLIPS) rather promotes 
formation of the death-inducing complex and subsequent necroptosis (Feoktistova et 
al., 2011). In addition, RIPK3 activity is also negatively controlled by the 
phosphatase Ppm1b through dephosphorylation (Chen et al., 2015). 
An additional RHIM-containing protein, TRIF is also capable of activating RIPK3, 
independently of RIPK1 (Mocarski et al., 2012; Dillon et al., 2014). TRIF is an 
adaptor protein of TLR3 and TLR4 signalling, and has been shown to mediate cell 
death upon TLR3 and TLR4 activation. Another RHIM-containing protein DAI is a 
cytosolic double-stranded DNA sensor, which is able to interact with RIPK1 and 
RIPK3 via RHIM domain upon viral infection (Upton et al., 2012). 
1.2.4 Crosstalk between NF-κB signalling and cell death pathways 
The transcpritional activity of NF-κB induces the expression of target genes including 
a wide range of pro-survival proteins which antagonise the action of cell death 
pathway (Kucharczak et al., 2003). This includes, for instance, cIAP1/2 and XIAP, c-
FLIP and Bcl-2 family member proteins, such as Bcl-2, Bcl-XL and A1. Also, it 
upregulates anti-oxidative protein and SODs, which quench ROS to prevent cell 
death mediated by oxidative stress in the liver (Kondylis et al., 2015). 
Additionally, recent studies demonstrated that NF-κB pathway components suppress 
cell death independently of NF-κB's transcriptional activation. Indeed, IKK1/2 and 
NEMO have an additional role in inhibiting RIPK1-dependent cell death in addition to 
their role in activating NF-κB (Dondelinger et al., 2015; Kondylis et al., 2015; Vlantis 
et al., 2016). Mechanistically, the IKK complex appears to phosphorylate RIPK1 
which prevents it from forming a death-inducing complex (Dondelinger et al., 2015). 
Also, RelA/p65 is capable of suppressing RIPK1-dependent apoptosis of intestinal 
Paneth cells and death of mouse embryos (Vlantis et al., 2016). Yet, it is still not 
entirely clear how RelA inhibits RIPK1-dependent cell death.  
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1.2.5 Implication of NF-κB and cell death pathways in mouse models of liver 
diseases 
Cell death is one of the central players in inflammation. Previous studies highlighted 
the significance of protection against cell death in order to maintain tissue 
homeostasis. For instance, genetic deletions of anti-apoptotic proteins Mcl-1 and 
Bcl-XL in liver parenchymal cells results in hepatocyte apoptosis and subsequent 
HCC formation (Weber et al. 2009, Hikita et al. 2012). These reports underpin the 
importance of apoptosis regulation to prevent liver inflammation and subsequent 
tumourigenesis. 
The fact that NF-κB is a pivotal player of inflammatory signalling has led scientists to 
investigate the role of NF-κB signalling in liver cancer. The first study of NF-κB 
signalling in liver carcinogenesis employed Mdr2 knockout mice (Pikarsky et al, 
2004).  In this model, suppression of canonical NF-κB signalling by hepatocyte-
specific expression of IκB super-repressor inhibits the progression to a malignant 
tumour via downregulation of anti-apoptotic factors (Pikarsky et al, 2004). In Mdr2 
knockout mice, NF-κB activation was mediated by TNF produced by adjacent 
endothelial cells and immune cells. Consequently anti-TNF therapy also inhibits 
tumour progression (Pikarsky et al, 2004). Therefore, at least in Mdr2 knockout mice, 
NF-κB signalling is a tumour-promoting factor. Furthermore, truncation of a tumour 
suppressor and negative regulator of NF-κB signalling CYLD in hepatocytes also 
leads to periportal hepatocyte apoptosis, hepatitis, hepatomegaly, fibrosis and 
cancer (Nikolaou et al, 2012), whereas systemic CYLD deletion apparently does not 
recapitulate this phenotype (Massoumi et al., 2006; Reiley et al., 2006; Zhang et al., 
2006). 
Lymphotoxins and their receptor LTβR are upregulated in patients suffering from 
viral hepatitis or HCC. Ectopic expression of LTα and LTβ specifically in hepatocytes 
(AlbLTαβ mice) leads to chronic hepatitis from 6 months of age and HCC at 12 
months (Haybaeck et al., 2009). Hepatitis and cancer development in AlbLTαβ mice 
were ameliorated by ablation of mature T and B cells by crossing to Rag1KO mice. 
This indicates that lymphocytes play a major role in promoting hepatitis triggered by 
lymphotoxins. More importantly, the pathology is also prevented by deletion of IKK2 
in hepatocytes. This evidence suggests that canonical NF-κB signalling in 
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hepatocytes, activated by lymphotoxins, is crucial for creating an inflammatory 
environment by producing chemokines including CCL2 and CXCL1 (Haybaeck et al., 
2009, Wolf et al, 2010).  
On the contrary to the studies demonstrating the pro-tumourigenic role of NF-κB, 
genetic models have illustrated the protective role of NF-κB against liver 
carcinogenesis. First, mice devoid of IKK2 specifically in hepatocytes are more 
susceptible to DEN-induced liver tumourigenesis (Maeda et al., 2005). IKK2 in 
hepatocytes suppresses DNA damage by a reduction in hepatic ROS via NF-κB 
activation (Maeda et al., 2005). Moreover, liver parenchymal deletion of NEMO 
triggers spontaneous hepatocyte apoptosis, fibrosis, steatohepatitis leading to 
eventual HCC formation (Luedde et al., 2007). This phenotype in NEMO-deficient 
livers is reversed by constitutive activation of IKK2 in hepatocytes (Kondylis et al., 
2015).  Furthermore, TAK1 deletion in hepatocytes results in early tumourigenesis 
and death of the animals (Betterman et al., 2010).  Thus, these results demonstrate 
that NF-κB signalling is required for protection against liver carcinogenesis. It 
appears that optimal control of NF-κB activation is crucial for maintaining liver 
homeostasis as the abrogation of both activator and inhibitor of NF-κB can be a 
cause of liver inflammation and cancer.  
Of note, deletion of NF-κB signalling components not only impairs NF-κB activation 
but also activates cell death pathways. Pasparakis and colleagues demonstrated 
that concomitant ablation of all the three NF-κB transcription factors, RelA, RelB and 
c-Rel, in mouse livers does not recapitulate the tumourigenic phenotype seen in 
NEMO-deficient livers, although it causes mild liver damage (Kondylis et al., 2015). 
RIPK1-dependent apoptosis plays a central role in initiating the inflammation and 
promotes carcinogenesis as co-ablation of RIPK1 and TRADD or inactivation of 
RIPK1 kinase activity prevents hepatocyte apoptosis and HCC in NEMO-deficient 
livers (Kondylis et al., 2015). Furthermore, caspase-8 deletion in hepatocytes also 
suppressed TAK1 deletion-mediated hepatocyte death and carcinogenesis (Vucur et 
al, 2013). This evidence suggests that apoptosis is a major driver of hepatitis-driven 




1.3 Linear ubiquitination 
1.3.1 Ubiquitination 
Ubiquitination is one of the post-translational protein modifications where one or 
more ubiquitin molecules are attached to a target protein. Ubiquitin is an 
evolutionarily conserved small protein, consisting of 76 amino acids (8.6 KDa) 
(Hershko and Ciechanover, 1998). There are four genes encoding ubiquitin in 
mammals. Ubiquitin proteins are generated as polyubiquitin, where ubiquitin moieties 
are fused in a head-to-tail configuration, or expressed as fusion proteins UbL40 and 
UbS27, a ubiquitin molecule conjugated to a ribosomal protein L40 and S27, 
respectively. These polyubiquitin precursors are cleaved by deubiquitinases to 
create a pool of free ubiquitin molecules (Kimura and Tanaka, 2010).  
Ubiquitination is coordinated by sequential actions of three classes of enzymes: 
ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2) and ubiquitin 
ligating enzymes (E3) (Hershko and Ciechanover, 1998). First, E1 activates ubiquitin 
in an ATP-dependent fashion to form an intermediate ubiquitin adenylate, followed 
by generation of a thioester bond between the C-terminal glycine residue of a 
ubiquitin and a catalytic cysteine residue of an E1 enzyme. The activated ubiquitin is 
subsequently transferred to a cysteine residue in the active site of E2, which is a 
ubiquitin-carrier protein. In the last step, an E3 ligase catalyses the attachment of 
ubiquitin to target proteins. H. sapiens bears only two E1 enzymes, approximately 40 
E2 enzymes and over 600 E3 ligases (Glickman and Ciechanover, 2002). 
Ubiquitin can be conjugated together to form polyubiquitin, which adds a layer of 
complexity to this protein modification. Ubiquitin has seven lysine residues (Lys6, 
Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63), and all of the lysines can be 
ubiquitinated. This type of ubiquitination results in the formation of an isopeptide 
bond between the carboxyl group of the C-terminal glycine of a ubiquitin and the ε-
amino group of a lysine residue of another ubiquitin moiety (Kulathu and Komander, 
2012). Additionally, an unconventional linkage was discovered and reported in 2006. 
The N-terminal methionine (Met1) of a ubiquitin moiety was found to be capable of 
mediating the di-ubiquitin linkage (Kirisako et al., 2006), where this peptide bond 
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generates the same polyubiquitins translated as ubiquitin precursors. Thus, 
depending on the lysine or methionine residue engaged in an inter-ubiquitin bond, 
two ubiquitin moieties can be tied with eight different possible di-ubiquitin linkages.  
Each type of di-ubiquitin linkages confers distinct conformation of polyubiquitin. Lys6-, 
Lys11- and Lys48-linked di-ubiquitins take packed structures due to intramolecular 
interactions, whereas Lys63- and Met1-linked di-ubiquitins display rather stretched 
structures (Kulathu and Komander, 2012). The divergent topologies of each linkage 
mediate individual biological outcomes as they determine which ubiquitin receptors 
are bound to which linkage type and to which signalling complex (Shimizu et al., 
2015). For instance, Lys48-linked polyubiquitin mediates the degradation of 
substrates, whereas Lys63- and Met1- linked polyubiquitin modulates intracellular 
signalling pathways (Kulathu and Komander, 2012). 
More recently, ubiquitin modifications are perceived to be far more complex. A 
substrate protein is not necessarily ubiquitinated with a single type of linkages. It can 
be a mixture of multiple linkage types; for instance, Lys63- and Met1-linked 
polyubiquitin coexists on the same signalling molecule in TLR signalling, hence 
creating hybrid ubiquitin chains (Emmerich et al., 2013; Emmerich et al., 2016).  
Furthermore, ubiquitin can be phosphorylated or acetylated. Proteomics studies 
identified several potential phosphorylation sites and acetylation sites in ubiquitin 
(Swatek et al., 2016). Whilst the role of ubiquitin acetylation still remains elusive, 
scientists have started to understand the role of ubiquitin phosphorylation. Ubiquitin 
is phosphorylated at Ser65 by PINK1 on depolarised mitochondria, and 
subsequently phosphorylated ubiquitin activates ubiquitin E3 ligase Parkin (Koyano 
et al., 2014; Kane et al., 2014). 
1.3.2 Linear ubiquitin and LUBAC 
Among the eight ubiquitin linkage types, Met1-linked, or linear ubiquitination is an 
emerging type of non-proteolytic ubiquitin modification (Kulathu et al., 2012). Linear 
ubiquitination was first identified to be engaged in IL-1 and TNF signalling where it 
regulates NF-κB and MAPK signalling (Tokunaga et al., 2009; Haas et al., 2009). 
Linear ubiquitin is present in diverse innate and adaptive immune signalling 
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pathways and regulates their outputs, which is covered in more detail in the review I 
wrote during the PhD programme (Shimizu et al., 2015). 
LUBAC is the only enzyme complex identified to date that generates the linear di-
ubiquitin linkage de novo. LUBAC consists of HOIP, HOIL-1 and SHARPIN, where 
HOIP is the catalytic core component of LUBAC. HOIP and HOIL-1 are RBR E3 
ubiquitin ligases, but HOIL-1 does not appear to have an E3 activity within LUBAC in 
cells, as the expression of the catalytically inactive mutant of HOIL-1 does not affect 
linear ubiquitin synthesis (Kirisako et al., 2006). Yet, HOIP alone is not sufficient to 
produce linear ubiquitin and it requires at least one of the other LUBAC components, 
HOIL-1 or SHARPIN, to do so efficiently (Gerlach et al., 2011, Ikeda et al., 2011, 
Tokunaga et al., 2011). This means that HOIP has a self-inhibitory regulation which 
is neutralised by binding to HOIL-1 or SHARPIN. HOIP interacts with the UBL 
domain of HOIL-1 and SHARPIN via its UBA domain (Kirisako et al., 2006; 
Tokunaga et al., 2011).   
The C-terminal RBR domain and linear ubiquitin chain determining domain (LDD) of 
HOIP are the minimal catalytic core capable of forming Met1-linked di-ubiquitin 
linkage (Smit et al., 2012, Stieglitz et al., 2013). HOIP acts as a RING/HECT hybrid 
E3 ligase, similar to other members of the RBR E3 proteins including Parkin 
(Stieglitz et al., 2012). As a first step, HOIP binds to ubiquitin-loaded E2 via its 
RING1 domain so that E2 and E3 catalytic centres are aligned for ubiquitin transfer 
(Lechtenberg et al., 2016). Ubiquitin is subsequently transferred from E2 to HOIP 
RING2 domain. Next, in the proximity of the catalytic cysteine, a histidine residue in 
RING2 acts as a basic residue to activate the ε-amino group of Met1. Activated Met1 
creates the thioester bond with the C-terminus of the proximal ubiquitin which is 
attached to catalytic cysteine (Stieglitz et al., 2013).  
Interestingly, a most recent study reported an allosteric regulation on HOIP by an 
additional ubiquitin molecule, which interacts with the third ubiquitin binding region 
(UBR3) of HOIP within its RBR domain (Lechtenberg et al., 2016). This allosteric 
regulation promotes a conformational change in HOIP's RBR domain to 
accommodate an activated ubiquitin, and thereby enables linear di-ubiquitin linkage 
formation. In accordance, the regulation via UBR3 is required for activation of HOIP 
E3 activity and NF-κB activating capacity. 
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In TNF signalling, where LUBAC was first identified in a signalling complex, LUBAC 
is recruited to the TNF-RSC depending on the E3 activity of cIAP1/2 and 
ubiquitinates RIPK1, NEMO, TRADD and TNFR1 (Haas et al., 2009; Gerlach et al., 
2011; Draber et al., 2015) (also see Figure 1.2). LUBAC not only regulates NF-κB 
and MAPK signalling but also, more importantly, prevents TNF-induced cell death 
(Haas et al., 2009; Gerlach et al., 2011; Ikeda et al., 2011; Peltzer et al., 2014). 
1.3.3 In-vivo function of linear ubiquitination 
The role of linear ubiquitin in animal models has been extensively examined using 
chronic proliferative dermatitis mice (C57BL/KaLawRij, referred to as cpdm mice). 
Cpdm mice harbour a single-base pair deletion in the first exon in the Sharpin gene 
leading to complete loss of the SHARPIN protein (Seymour et al, 2007). Cpdm mice 
develop chronic proliferative dermatitis and multi-organ inflammation, such as in the 
liver, intestine and joint, at 3-4 weeks of age (HogenEsch et al., 1992). In addition, 
cpdm mice display immune aberrations such as loss of Peyer's patches and 
disorganisation of lymphoid architecture (HogenEsch et al., 1999). The loss of 
SHARPIN is causative for both inflammatory and lymphoid phenotypes (Seymour et 
al, 2007). 
Researchers investigated the role of inflammatory mediators in cpdm mice to 
understand how cpdm mice develop spontaneous inflammation. However, 
lymphocyte or eosinophil depletion is unable to ameliorate inflammation. By contrast, 
cpdm skin transplantation to nude mice transferred the donor's skin pathology to the 
recipient (Gijbels et al., 1995), which suggested that the aetiology of the dermatitis is 
intrinsic in the cpdm skin. 
Strikingly, genetic ablation of TNF or TNFR1 rescues the inflammatory phenotype in 
cpdm mice; however, their lymphoid aberration is unaltered by TNF or TNFR1 
deletion (Gerlach et al., 2011; Kumari et al., 2014). TNF-induced cell death is 
causative for cpdm phenotype, as genetically demonstrated by the following studies; 
co-deletion of RIPK3 and heterozygosity of caspase-8 (Rickard et al., 2014), 
epidermal ablation of FADD with systemic deletion of RIPK3 (Kumari et al., 2014), 
and RIPK1 kinase inactivation (Berger et al., 2014) corrected the cpdm phenotypes, 
including lymphoid distortion. These studies together illustrated that the inflammatory 
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and immune phenotype is mediated by cell death triggered by SHARPIN deficiency, 
which firmly support the notion that cell death is a leading cause of inflammation.  
In contrast to cpdm mice, deletion of the catalytic component of LUBAC, HOIP, leads 
to embryonic lethality at mid-gestation due to aberrant endothelial cell death (Peltzer 
et al., 2014). This cell death is rescued by TNFR1 deletion, suggesting that TNFR1-
mediated cell death is responsible for mid-gestational death of the animals, although 
it does not rescue their death at late gestation. Mutant mice expressing catalytically 
inactive HOIP also suffer from embryonic lethality at a similar stage to HOIP-deficient 
embryos (Emmerich et al., 2013). Our group also found that HOIL-1 knockout mice 
manifest an equivalent phenotype to HOIP knockout animals (Peltzer et al., 
manuscript in preparation), whilst HOIL-1 knockout mice were previously reported to 
be viable by another group (Tokunaga et al., 2009). HOIL-1-deficient mice made by 
Tokunaga et al. exhibit amylopectin-like deposits in the myocardium but show 
minimal signs of hyper-inflammation (MacDuff et al., 2015). Moreover, loss-of-
function mutations of HOIL-1 and HOIP genes in human are causative for 
autoinflammation, immunodeficiency, amylopectinosis, and lymphangiectasia 
(Boisson et al., 2012; Boisson et al., 2015). 
1.3.4 LUBAC substrates and regulation of signalling 
Recent studies identified several targets of linear ubiquitination in multiple immune 
signalling pathways. Among them, TNFR1 and NOD2 signalling pathways are best 
characterised. In TNFR1 signalling, RIPK1 and NEMO are identified to be linearly 
ubiquitinated upon stimulation by mass-spec analysis (Gerlach et al., 2011). 
Furthermore, affinity purification assay for linear ubiquitin unravelled that TNFR1 and 
TRADD are additional substrates of LUBAC (Draber et al., 2015).  
In NOD2 signalling, RIPK2 is the only protein that is linearly ubiquitinated and 
predominantly ubiquitinated upon MDP stimulation, as defined by mass-spec 
analysis using stable isotope labelling with amino acids in cell culture (SILAC) 
approach (Fiil et al., 2013). Functionally, linear ubiquitination of RIPK2 is required for 
optimal NF-κB and MAPK signalling outputs by recruiting IKK complex.  
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1.3.5 Deubiquitinases for linear ubiquitin chains 
Deubiquitinases (DUBs) remove ubiquitin from substrates and process ubiquitin 
precursors after translation of initial polyubiquitin (Komander, 2009). Functions of 
DUBs are characterised by which ubiquitin chain they hydrolyse. Biological roles of 
DUBs on non-degradative ubiquitin modifications, including on Met1-mediated 
linkages, is at present not entirely clear. Interestingly, two DUBs, OTULIN and CYLD 
are capable of cleaving Met1-linked ubiquitin, and they have recently been shown to 
be a part of a complex with LUBAC (Figure 1.4) (Takiuchi et al., 2014). Of note, 
LUBAC-OTULIN and LUBAC-CYLD complexes exist in a mutually exclusive fashion 
(Draber et al., 2015). 
1.3.5.1 OTULIN 
OTULIN, or FAM105B, is a member of the OTU family of DUBs (Keusekotten et al., 
2013). While the other 14 annotated OTU DUBs do not cleave Met1-linked 
diubiquitin, OTULIN is highly specific for cleaving linear ubiquitin linkage as 
compared to Lys63-linked di-ubiquitin (more than 100-fold) and it retains its 
specificity even at a very high concentration (Keusekotten et al., 2013; Rivkin et al., 
2013; Hospenthal et al., 2015). OTULIN interacts with the PUB domain of HOIP via 
its PIM motif, which is regulated by phosphorylation of Tyr56 in OTULIN. This 
phosphorylation prevents the binding of OTULIN to HOIP (Schaeffer et al., 2014, 
Elliot et al., 2014). However, it is unknown which kinase and phosphatase control 
phosphorylation state of the tyrosine residue of OTULIN.  
In line with a role for OTULIN in counteracting linear ubiquitination, OTULIN 
deficiency in cells greatly enhances the amount of linear ubiquitin in the cytosol 
(Draber et al., 2015). The role of OTULIN in TNF and NOD2 signalling has been 
controversial. Whilst a study identified OTULIN as a component of the TNF-RSC by 
mass spectrometry analysis (Wagner et al., 2016), our laboratory reported that 
OTULIN is not recruited to TNF- and NOD2- signalling complexes and does not 
drastically affect linear ubiquitination in these complexes (Draber et al., 2015). 
Furthermore, other groups claimed that OTULIN overexpression delays LUBAC-
mediated NF-κB and JNK activation upon TNF, whereas the inducible knockdown of 
OTULIN increases these signalling outputs (Keusekotten et al., 2013; Fiil et al., 
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2013).  It appears that the interaction of OTULIN within those complexes is transient 
and unstable and therefore in some cases OTULIN does not drastically affect the 
signalling outcome of those signalling when expressed at physiological levels. 
Loss-of-function mutations of Otulin/Fam105b gene in mice are causative for the 
gumby phenotype, which manifests reduced craniofacial vasculature and embryonic 
lethality at mid-gestation (Rivkin et al., 2013). Gumby mice exhibit abnormal vessel 
branching in the head and trunk, whereas the major vessels develop normally. 
OTULIN is shown to bind to dishevelled 2(DVL2), a Wnt signalling adaptor, 
suggesting that linear ubiquitination could be involved in canonical Wnt signalling 
and mediates angiogenesis during development (Rivkin et al., 2013). Yet, the 
mechanism as to how LUBAC and OTULIN would regulate Wnt signalling remains 
enigmatic.  
1.3.5.2 CYLD 
Cylindromatosis (CYLD) is a tumour suppressor belonging to the USP family of 
DUBs. CYLD preferentially cleaves Lys63- and Met1- ubiquitin linkages. Mutations in 
Cyld gene are responsible for familial cylindromatosis (Bignell et al., 2000), where 
the majority of mutations are clustered around the catalytic USP domain. Loss of 
CYLD leads to aberrantly increased activation of NF-κB (Sun, 2010). Loss of CYLD 
function in mice is associated with the formation of inflammation-associated cancers 
including colorectal, skin and liver cancer (Massoumi et al., 2006; Zhang et al., 2006; 
Nikolaou et al., 2012). Furthermore, CYLD is downregulated in multiple cancers such 
as colon and liver cancer in human (Pannem et al., 2014). CYLD plays a role in 
various immune signalling pathways and hydrolyses ubiquitin chains on several 
signalling components and thereby shut off signal transduction. 
CYLD is also important for cell death induction via TNFR1 as it has been shown to 
be required for the induction of necroptosis by facilitating the formation of complex II 
of TNFR1 signalling. Activated caspase-8 can cleave CYLD which results in its 





Figure 1.4 LUBAC-mediated signalling. LUBAC-CYLD complex appears to be predominantly 
recruited to the receptor signalling whereas LUBAC-OTULIN complex stays in the cytosol. Recruited 
LUBAC ubiquitinates substrates to facilitate signalling, which is counteracted by CYLD and, possibly, 
OTULIN to regulate signalling. In addition to ubiquitination and deubiquitination, linear ubiquitin 
binders are bound on linear polyubiquitin, and further potentiate or regulate its signalling outputs.  
 
CYLD is constitutively associated with LUBAC (Takiuchi et al., 2014). However, the 
association is indirect; SPATA2 has been identified as a bridging factor between 
CYLD and LUBAC, and is essential for CYLD to be recruited to the TNF-RSC 
(Wagner et al., 2016; Kupka et al., 2016). SPATA2 is bound to the PUB domain of 
HOIP and the USP domain of CYLD. Also, the recruitment of CYLD to the TNF-RSC 
is dependent on the scaffolding function of HOIP, but not on its catalytic activity 
(Draber et al., 2015). It appears that LUBAC, SPATA2 and CYLD are together 
recruited to the TNF-RSC and CYLD inhibits LUBAC-mediated NF-κB activation in 




1.3.6 Linear ubiquitin-binding proteins 
LUBAC regulates the function of its substrates by ubiquitination, but ubiquitins must 
be recognised by other proteins to fully exert its function to signal to the downstream. 
Figure 1.4 indicates how LUBAC can mediate the signalling by ubiquitination, and 
ubiquitin is 'read' by ubiquitin receptors, or binders. Within ubiquitin receptors, most 
of the ubiquitin binding domains interact specifically with particular types of ubiquitin 
linkages. Therefore these binders are recruited to specific ubiquitin linkages on 
particular targets in signalling complexes (Shimizu et al., 2015).  
Studies have shown that the ubiquitin binding domains in NEMO, ABIN-1 and A20 
bind preferentially to linear ubiquitin for Met1-linked polyubiquitin. It is crucial for 
understanding the biological role of linear ubiquitination by reviewing the nature of 
these proteins. 
1.3.6.1 NEMO 
The adaptor protein NEMO/IKKγ is engaged in the IKK complex with the kinase 
heterodimer IKKα/β, which phosphorylates IκBα and activates canonical NF-κB 
signalling. NEMO harbours a C-terminal ubiquitin recognition motif, the UBAN motif. 
The UBAN motif specifically recognises linear ubiquitin over Lys48- and Lys63-linked 
polyubiquitin (Rahighi et al., 2009). NEMO mutations are causative for incontinentia 
pigmenti and anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) 
(Aradhya et al., 2001; Döffinger et al., 2001). Noteworthy, mutations in the UBAN 
domain of NEMO are linked to EDA-ID (Döffinger et al., 2001; Hubeau et al., 2011). 
A point mutation in its UBAN motif hampers the binding to polyubiquitins, particularly 
linear chains, and thereby dampens IKK activation and increases susceptibility to 
TNF-induced cell death, despite an unaltered folding of NEMO protein (Wu et al., 
2008; Rahighi et al., 2009; Hubeau et al., 2011; O'Donnell et al., 2012).  
Loss of NEMO in different tissues results in severe inflammation. NEMO deletion in 
skin epithelium leads to perinatal lethality preceded by dermatitis, which is 
reminiscent of incontinentia pigmenti phenotype in humans (Nenci et al., 2006). Also, 
the intestinal ablation of NEMO results in severe spontaneous colitis (Nenci et al., 
2007). In both cases, TNF drives the inflammation and, at least in the latter, 
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inflammation due to NEMO deficiency was driven by RIPK1-dependent cell death 
(Vlantis et al., 2016). By contrast, LPC-specific deletion of NEMO leads to TNF-
independent steatohepatitis and liver carcinogenesis (Luedde et al., 2007; Ehlken et 
al., 2014). NEMO together with IKKα/β suppresses activation of RIPK1 to undergo 
cell death (Dondelinger et al., 2015). Thus, the recognition of linear ubiquitin is 
essential for NEMO to optimally activate NF-κB signalling and prevent aberrant cell 
death. 
1.3.6.2 ABIN-1 
ABIN-1 harbours a C-terminal UBAN motif, similar to NEMO, which preferentially 
binds to linear ubiquitin as compared to Lys63-linked chains (Nanda et al., 2011). 
ABIN-1 suppresses NF-κB activation in TNFR1 and TLR signalling by binding to 
NEMO (Mauro et al., 2006). ABIN-1 restricts TNF-induced cell death by binding to 
ubiquitin chains (Oshima et al., 2009).  
Deletion of ABIN-1 in mice causes lethality late during embryonic development. Its 
lethality is rescued by concomitant TNF ablation, and TNF-induced cell death 
appears to be accountable for the cause of death of ABIN-1-deficient embryos 
(Oshima et al., 2009). A missense mutation in its UBAN domain leads to loss of 
binding capacity to Met1- and Lys63-linked ubiquitins and cells expressing this 
mutant fail to protect against TNF-induced cell death (Oshima et al., 2009; Nanda et 
al., 2011). The knock-in mice of UBAN mutant of ABIN-1 spontaneously develop 
immune defects including lymphadenopathy and autoimmunity. Interestingly, these 
immune abnormalities are corrected by MyD88 deficiency (Nanda et al., 2011). Yet, 
the UBAN mutant mice did not phenocopy the embryonic lethality of ABIN-1-deficient 
mice, suggesting that ABIN-1 has other regulatory domains to modulate immune 
signalling. 
1.3.6.3 A20 
A20 (also known as TNFAIP3) has an OTU domain at the N-terminus and seven ZF 
domains at the C-terminus (Ma et al., 2012). The function of A20’s DUB activity has 
been controversial. A20 was initially thought to act as a suppressor of NF-κB by 
cleaving Lys63-linked ubiquitin linkages (Wertz et al., 2004, Wertz et al., 2015). 
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However, other studies indicated that A20 is incapable of hydrolysing Lys63-linked 
ubiquitin linkages (Lin et al., 2008; Mevissen et al., 2013; Ritorto et al., 2014). 
Following studies showed that A20 binds to linear ubiquitin and stabilises it and that, 
on the other hand, the presence of linear ubiquitin prevents the DUB activity of A20 
(Draber et al., 2015; Wertz et al., 2015). 
A20 inhibits activation of NF-κB in various immune signalling including TNFR1, CD40, 
IL-1R/TLR (Wertz et al., 2004; Turer et al., 2008; Hitotsumatsu et al., 2008, Chu et 
al., 2011). A20-deficient mice develop multi-organ inflammation in a MyD88-
dependent manner, and suffer from lethality within two weeks of birth (Lee et al., 
2000; Turer et al., 2008). A20-deficient cells show TNF-induced NF-κB 
hyperactivation and also increased cell death. However, inactivation of A20’s DUB 
activity in the OTU domain does not elicit spontaneous inflammation in mice, and 
neither is it required for prevention of TNF-induced cell death (De et al., 2014; 
Draber et al., 2015). The inactive mutant only marginally impacts NF-κB activation in 
macrophages and dendritic cells (De et al., 2014).  The OTU domain appears to 
regulate ubiquitination of TNFR1 and contribute to the inhibition of inflammation, but 
the precise mechanism is unclear (Wertz et al., 2015). 
A20 has two ubiquitin binding sites in its C-terminus, the ZF4 and ZF7 domains. The 
ZF4 motif is the preferential binding site to Lys63-linked, as compared to Lys11-, 
Lys48- or Met1-linked polyubiquitin (Bosanac et al., 2010). Mutation of ZF4 in mice 
does not affect their development (Lu et al., 2013), although ubiquitin binding of ZF4 
is required for attenuation of TNFR1 signalling (Bosanac et al., 2010; Lu et al., 2013; 
Wertz et al., 2015). In contrast to ZF4, the ZF7 domain specifically binds to linear 
ubiquitin and is essential for recruitment of A20 to the TNF-RSC, depending on the 
presence of linear polyubiquitin (Tokunaga et al., 2013; Draber et al., 2015). The ZF7 
motif directly inhibits TAK1-dependent activation of NF-κB signalling by binding to 
polyubiquitin chains (Skaug et al., 2013, Verhelst et al., 2013, Tokunaga et al., 2013). 
Also, TNF-induced cell death was suppressed by linear ubiquitin binding of ZF7 
(Draber et al., 2015). It appears that concerted actions of the OTU, ZF4 and ZF7 
domains are essential for the anti-inflammatory function of A20 as none of the 







1.4 Aims of the project 
 
Our laboratory and others have investigated the role of LUBAC and established that 
linear ubiquitination regulates NF-κB signalling as well as MAPK signalling and 
prohibits TNF-induced cell death. Furthermore, perturbation of TNFR1 signalling is 
strongly associated with liver pathogenesis in mice. 
The aim of this research is to elucidate the role of linear ubiquitination in the liver 
parenchyma by observing how linear ubiquitination or its loss impacts inflammation 
and cell death in the development of hepatitis, and possibly, liver cancer formation. 
The major research questions are: 
 
1. Does perturbation of linear ubiquitination in hepatocytes exacerbate or prevent the 
induction of hepatitis and/or HCC in vivo? If so, what is the mechanism engaged? 
2.  How does perturbation of linear ubiquitination in hepatocytes alter their response 
to TNF and other death receptor ligands, such as TRAIL and CD95L, in terms of 
gene activation and cell death induction? 
 
To answer these questions, I have utilised a mouse model relying on HOIP 
deficiency in liver parenchymal cells. On the basis of this model, I have investigated 
the role of linear ubiquitination in regulating cell death and inflammation in the liver 
and how this affects liver carcinogenesis with the aim to broaden our understanding 






Chapter 2  
2 Material and methods 
 
2.1 Material 
2.1.1 Chemical and reagents  
All the chemicals and reagents used in this thesis were purchased from the following 
companies unless stated otherwise: Abcam, Biovision, Merck, Invitrogen, Pierce, 
R&D systems, Roche, Roth and Sigma-Aldrich. All chemicals were purchased in pA 
quality unless indicated otherwise. 
2.1.2 Inhibitors 
inhibitor name manufacturer 
Complete Protease Inhibitor Cocktail Roche 
PhosSTOP Roche 
Sodium fluoride (NaF) Sigma-Aldrich 
Sodium Orthovanadate (Na3VO4) Sigma-Aldrich 
Necrostatin-1 Sigma-Aldrich 
Nec-1s Biovision 
QVD-fmk (QVD) R&D systems 
zVAD-fmk (zVAD) Abcam 
 
2.1.3 Buffers and solutions 
Primary antibody diluent   2.5% (w/v) BSA in PBS-T 
Blocking Buffer     2.5% (w/v) skimmed milk in PBS-T  
Citrate Buffer     10 mM sodium citrate, pH 6.0 
Freezing medium (for cells)  90 % FCS (v/v) 10 % DMSO (v/v) 
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IP-lysis Buffer 30 mM Tris-Base, 120 mM NaCl,   2 mM 
EDTA, 2 mM KCl, 10 % Glycerol (v/v), 1 % 
Triton X-100 (v/v)  
PBS 137 mM NaCl, 8.1 mM Na2HPO4, 2.7 mM 
KCl, 1.5 mM KH2PO4 
PBS-T     PBS, 0.05% (v/v) Tween-20 
Liver perfusion buffer NaCl 8 g/L, KCl 0.2 g/L, Na2HPO4 33 mg/L, 
HEPES 2.38 g/L, pH 7.65 
RIPA buffer: 50 mM Tris HCl pH 8.0, 150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% 
SDS 
Stripping buffer    50 mM glycine, pH 2.3 
TBS:      150 mM NaCl, 20 mM Tris, pH7.6 
TEX buffer:     10 mM Tris, 1 mM EDTA,    
      0.1% Triton X-100 pH 8.0 
Transfer buffer: 25 mM bicine, 25 mM Tris, 1 mM EDTA, 
10% Methanol (v/v), pH 7.2 
Tris-EDTA buffer:    10 mM Tris, 1 mM EDTA, pH 8.0 
 
2.1.4 Biological agents 
agent source 
His-TNF previously produced in E.coli and purified in our laboratory 
(kindly provided by Dr Peter Draber) 
iz-TRAIL (mouse) produced in E.coli and purified  
CD95L-Fc previously produced in HEK293T cells (kindly provided by 










Bax Santa Cruz sc-7480 mouse IgG2b 
Bcl-2 Santa Cruz sc-7382 mouse IgG1 
Bcl-xL Cell signaling 2764 rabbit 
Bid R&D systems AF860 goat 
caspase-8 Enzo Life Sciences ALX-804-447 rat 
c-FLIP Adipogen AG-20B-0005 rat 
cIAP1/2 R&D systems 315301 mouse IgG2a 
cleaved caspase-3 Cell Signaling 9661 rabbit 
cleaved caspase-8 Cell Signaling 9429 rabbit 
ERK1/2 Cell Signaling 9102 rabbit 
FADD Assay Design AAM-121 mouse IgG1 
GAPDH Abcam ab8245 mouse IgG1 
HOIL-1 in-house - mouse IgG2a 
HOIP in-house - rabbit 
IB Cell Signaling 9242 rabbit 
JNK Cell Signaling 9258 rabbit 
Mcl-1 Cell signaling 94296 rabbit 
phospho-ERK  Cell Signaling 9101 rabbit 
phospho-IκBα Cell Signaling 9246 mouse IgG1 
phospho-JNK  Cell Signaling 4671 rabbit 
RIPK1 BD Biosciences 610459 mouse IgG2a 
RIPK3 Enzo Life Sciences ADI-905-242 rabbit 
SHARPIN Proteintech 14626-1-AP rabbit 
XIAP Cell Signaling 2042 rabbit 
 











Unconjugated primary antibody for immunofluorescence 




F4/80 AbD serotec MCA497G rat 
γH2AX Cell Signaling 9718 rabbit 
HNF4 Abcam ab41898 mouse IgG2a 
Ki-67 Abcam ab16667 rabbit 
Ly6G Biolegend 4767 rat 
p21 BD Biosciences 556430 mouse IgG1 
 
Conjugated primary antibody for flow cytometry 




B220 Biolegend 103243 Brilliant Violet 650 
CD3 Biolegend 100326 PerCP 
CD4 eBioscience 25-0041-82 PE-Cy7 
CD45 Biolegend 103128 Alexa Fluor 700 
CD8 Biolegend 100714 APC-Cy7 
F4/80 Biolegend 123110 PE 
Ly6G Biolegend 127606 FITC 
NK1.1 Biolegend 108731 Brilliant Violet 421 
 
2.1.6 Cell culture media and supplements 
Antibiotic-Antimycotic (100x)   Gibco 
BSA fraction V (7.5%)    Gibco 
DMEM      Gibco 
PenStrep (100x)     Gibco 
Trypsin/EDTA     Gibco 





2.1.7 Ready-to-use kits and solutions 
BCA Protein assay   Pierce 
ECL Plus   PerkinElmer 
RevertAid cDNA synthesis kit   Thermo Scientific 
RNeasy mini kit   Qiagen 
TUNEL   Millipore 
TSA Ampflification kit   PerkinElmer 
2.1.8 Consumables 
Cell Culture Petri dishes     TPP 
Cell Culture Plates (6-, 12-, 24-well)   TPP 
Cell strainer (40 μm, 70 μm)   BD Biosciences 
Conical tubes (15 ml and 50 ml)    TPP  
Cryogenic vials      Nunc 
Dialysis membrane     KMF 
LDS-Sample buffer      Invitrogen 
NuPAGE® 4-12% Bis-Tris Gels   Invitrogen 
PCR Tubes       StarLab 
Pipette tips (0.1-10, 1-200, 101-1000 μl)  StarLab 
Plastic pipettes (5 ml, 10 ml and 15 ml)   StarLab 
Polypropylene round bottom tube (5 ml)   BD Biosciences 
Round and flat bottom 96-well test plates  TPP 
Safe-Lock Reaction Tubes (1,5ml, 2 ml)   Eppendorf 
SeeBlue Plus2 Pre-Stained Standards  Invitrogen 
Single-Use Syringe (1ml, 5 ml, 50 ml)  Terumo 
Single-Use Scalpel      Feather 
Single-Use Needles     BD Biosciences 
SmartLadder DNA Standards   Eurogentec 
Sterile filter (0.22 μm)     Millipore  
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Tissue Culture flasks (75, 150 cm2)  TPP 
Whatman paper      Schleicher&Schuell  
X-Ray film       VWR 
2.1.9 Instruments 
Accuri C6      BD Biosciences 
Blotting equipment      Invitrogen 
Digital Camera      Olympus 
Evos FL      Life Technologies 
Fortessa LSR II     BD Biosciences 
Freezer -20°C      Liebherr 
Freezer -80°C      Forma Scientific 
Gene Amplification PCR system 9700   Applied Bioscience 
Light Microscope      Zeiss 
LaboStar™ TWF Water Purification  Evoqua 
Microwave       AEG 
Mithras      Berthold 
Multiskan Ascent      Thermo Labsystems 
NanoDrop Spectrophotometer ND-1000   NanoDrop Technologies 
pH Meter       Mettler 
Pipetboy      Integra Bioscience and StarLab 
Pipettes (10 μl, 100 μl, 200 μl, 1 ml)   Gilson and Eppendorf 
Power Supply for agarose gels    BioRad 
Table Centrifuge Biofuge     Heraeus 
Thermomixer compact     Eppendorf 
Vortex       Heidolph 





Adobe Photoshop CS6     Adobe 
Adobe Illustrator CS6    Adobe 
ApE       Wayne Davis (University of Utah) 
Ascent Software Version 2.6    Thermo Labsystems 
EndNote      Thomson Reuters 
FACSDiva      BD Biosciences 
FlowJo 7.6.5      TriStar 
GraphPad Prism 6     GraphPad Software 
ImageJ      NIH 
Microsoft Excel 2010    Microsoft 
Microsoft Powerpoint 2010    Microsoft 
Microsoft Word 2010     Microsoft 
ND1000 V3.3.0      NanoDrop Technology 
 
2.2 Cell biological methods 
2.2.1 Isolation and culture of mouse primary hepatocytes 
Primary hepatocytes were isolated from 7-12 week-old mice. First, mice were 
anaesthetised with ketamine and xylazine. Mice were cannulated via the inferior 
vena cava and subsequently the portal vein was incised. Mouse livers were perfused 
with warm perfusion buffer supplemented with 0.5 mM EDTA for 7 minutes. The 
Second perfusion with warm perfusion buffer plus 0.5 mg/ml collagenase (Sigma, 
C5138) and 10 mM CaCl2 was subsequently performed for 3 minutes. Digested 
livers were isolated in warm hepatocyte culture medium (William's E medium 
Glutamax supplement with 1x Antibiotic-antimycotic, 0.1 % (w/v) BSA fraction V and 
25 nM dexamethasone (Sigma)) with 10% FCS. Liver lobules were opened with 
forceps and scissors and vigorously shaken in the medium to release cells. Cells 
were passed through 70 um nylon mesh and spun at 29×g for 2 minutes at room 
temperature. Cell pellets were washed twice with hepatocyte culture medium with 
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FCS. Live cell numbers were counted by means of trypan blue exclusion. Isolated 
hepatocytes were plated on plates coated with collagen type I (Sigma, C3867) in 
hepatocyte culture medium with 10% FCS at 37ºC in humidified 5% CO2 chamber. 
The culture media were replaced 3-4 hours after plating with hepatocyte culture 
medium without FCS. 
2.2.2 Cell viability assay 
Culture media were removed and primary hepatocytes were lysed in diluted Cell 
Titer Glo solution (1:6 in PBS) (Promega). Cell lysates were incubated on a shaker 
for 10 minutes, and lysates were transferred to opaque 96-well plates for 
measurement. Luminescence reflecting the ATP level in cells was quantified with 
Mithras (Berthold). 
 
2.3 Biochemical methods 
2.3.1 iz-TRAIL production from E.coli 
Endotoxin-free isoleucine zipper-tagged murine TRAIL (izTRAIL) was purified from 
Rosetta strain of E.coli transformed with plasmid encoding izTRAIL as described by 
Ganten et al. (Ganten et al., 2005). E.coli lysate were subjected to a sequential 
purification employing AKTA micro system with hydroxyapatite column and Ni-NTA 
column to obtain concentrated fraction. Purified fractions were evaluated by means 
of UV absorbance, Bradford protein assay and SDS-PAGE. Level of contaminating 
LPS was examined by LAL assay. 
2.3.2 Preparation of cell lysates from primary cells for western blot 
Cells were lysed with ice-cold IP lysis buffer supplemented with Complete protease 
inhibitor cocktail (the solution prepared by dissolving a tablet in water, and added to 
lysis buffer in 1:50), 10 mM NaF and 1mM Na3VO4. Lysates were spun at 13300 rpm 
at 4°C for 15 minutes to remove insoluble fraction. Supernatants were mixed with 4x 
LDS sample buffer with 50 mM DTT (3:1) and boiled at 92°C for 5 minutes for PAGE. 
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2.3.3 Liver lysate preparation for western blot 
Livers were dissected from 4 week-old mice, snap-frozen in liquid nitrogen and 
stored at -80ºC until the following manipulation. Frozen livers were processed with a 
mortar and a pestle pre-chilled with liquid nitrogen until tissues became a fine 
powder. Processed livers were incubated in ice-cold RIPA buffer with Complete 
protease inhibitor cocktail solution (1:50) and PhosSTOP soliution (1:50) at 4ºC. 
Lysates were vortexed briefly and sonicated for 20 seconds four times, with one-
minute intervals on ice between each sonication. Lysates were incubated with 
continuous inversion for another 10 minutes. Samples were spun at 15000 g at 4ºC 
for 15 minutes to remove insoluble fraction.  
2.3.4 Determination of protein concentration 
Protein concentrations of liver lysates were determined by BCA protein assay 
(Pierce) with BSA as a protein standard. RIPA buffer was added to each sample to 
adjust protein concentration. 
2.3.5 Immunoprecipitation 
For immunoprecipitation for FADD-associated complex, cell lysates were diluted in 
IP lysis buffer. Lysates were pre-cleared with Sepharose CL-4B (Sigma) for 2 hours. 
Protein G-coupled sepharose (GE) was blocked with 1% BSA in IP lysis buffer for 1 
hour and washed extensively with IP lysis buffer prior to incubation. Pre-cleared 
lysates were incubated overnight with blocked Protein G-coupled sepharose and 
anti-FADD (M-19) antibody or isotype control, normal goat IgG (Santa Cruz), at 4ºC. 
Beads were washed 5 times with ice-cold IP lysis buffer and vortexed and proteins 
were eluted in 1x LDS buffer at 92ºC.  
2.3.6 Polyacrylamide gel electrophoresis 
Denatured lysates were separated on 4-12% Bis-Tris NuPAGE gel (Invitrogen) with 
MOPS buffer at 80 V for 15 min and at 180 V for 50 min. 
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2.3.7 Western blotting 
Proteins separated on polyacrylamide gels were transferred to nitrocellulose-based 
membranes by wet or semi-dry transfer using 1x transfer buffer. Membranes were 
blocked with blocking buffer for 1 hour and they were washed briefly with PBS-T and 
were incubated overnight with primary antibodies diluted in 2.5% (w/v) BSA (VWR) in 
PBS-T plus 0.1% (w/v) sodium azide. Membranes were washed briefly with PBS-T 
and were incubated with HRP-conjugated secondary antibodies for 1-2 hours. 
Membranes were washed extensively with PBS-T (at least 3 times) and developed 
with ECL plus substrate (Pierce) using X-ray films (VWR). 
2.3.8 Stripping of Western blot membranes 
Protein-transferred membranes were incubated with acidic stripping buffer (pH 2.3) 
to remove antibodies prior to the incubation with another primary antibody of the 
same host/isotype as previously used. 
2.3.9 Tissue RNA extraction and RT-qPCR 
Snap-frozen liver pieces were broken into fine powder with a mortar and a pestle and 
RNA was extracted from livers using RNeasy Mini kit (Qiagen). Purified RNA was 
subsequently employed for cDNA synthesis using RevertAid First Strand cDNA 
Synthesis Kit and poly A primer (Thermo Scientific). Synthesised cDNA was used for 
RT-PCR, with ROX polymerase mix, Universal Probe system (Roche) and specific 
primers: 
IL-6 forward GCTACCAAACTGGATATAATCAGGA 
IL-6 reverse CCAGGTAGCTATGGTACTCCAGAA 
TNF forward CTGTAGCCCACGTCGTAGC 
TNF reverse TTGAGATCCATGCCGTTG 
Hprt forward TGATAGATCCATTCCTATGACTGTAGA 
Hprt reverse AAGACATTCTTTCCAGTTAAAGTTGAG 
Light forward CTGCCAGATGGAGGCAAA 
Light reverse GGTCCACCAATACCTATCAAGC 
LTb forward GGGGAACCAGAAACTGACCT 
LTb reverse CCTTGCCCACTCATCCAA 
CCL3 forward TGCCCTTGCTGTTCTTCTCT 
CCL3 reverse GTGGAATCTTCCGGCTGTAG  
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CXCL1 forward GACTCCAGCCACACTCCAAC 





2.4 Animal studies  
 
All the animal studies stated are conducted according to the appropriate licence 
under Animals (Scientific Procedures) Act 1986. 
2.4.1 Liver-specific HOIP knockout mice 
HOIP-floxed mice were generated at the Walter and Eliza Hall (Melbourne, Australia) 
(Peltzer et al., 2014). HOIP-floxed mice were subsequently crossed to Alb-Cre mice 
(purchased from Jackson laboratories) for analysis. Both strains had and were 
maintained in C57BL/6 background. Mice were maintained in Charles River (Margate, 
UK) or UCL Biological Service Unit (London, UK) under the specific pathogen-free 
condition and 12-hour dark/light cycle, and fed ad libitum with standard chow.  
2.4.2 Crossings 
TNFR1 knockout mice (Pfeffer et al., 1993) were obtained from Jackson laboratories. 
They were derived from mixed 129S2/Sv and C57BL/6 background but were 
maintained in C57BL/6 background. Caspase-8 knockout mice were kindly provided 
by Dr William Kaiser, which were maintained in C57BL/6 background. MLKL 
knockout mice were generated in C57BL/6 background in our laboratory using 
transcription activator-like effector nuclease (TALEN) designed by Mr Sebastian 
Kupka. Liver-specific HOIP knockout mice were crossed to these mice for analysis.  
2.4.3 Genotyping 
Mice were sampled at 2-3 weeks of age for genotyping. Ear or tail samples were 
lysed in genotyping lysis buffer at 95°C for 30 min, and neutralised with an equal 
amount of genotyping neutralising buffer. Samples were preserved at 4°C until use. 
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PCR mix was prepared with 5 Prime master mix or Dream Taq (Thermo Fisher 
Scientific) and appropriate sets of primers: 
 
HOIP forward   CTCATTTGAATTCTATGATGC 
HOIP reverse GAAACAGGGACCAGGAGT 
Cre forward TTGCCCCTGTTTCACTATCCAG 
Cre reverse TGCTGTTTCACTGGTTATGCGG 
TNFR1 WT TGTGAAAAGGGCACCTTTACGGC  
TNFR1 common GGCTGCAGTCCACGCACTGG 
TNFR1 mutant ATTCGCCAATGACAAGACGCTGG 
Casp8 WT forward GTAGAAATGGAGAAGAGGACCATG 
Casp8 KO forward TTGAGAACAAGACCTGGGGACTG  
Casp8 reverse GGATGTCCAGGAAAAGATTTGTGTC 
MLKL common forward CAAGGAAAGAAGAACCTGCCCGA 
MLKL WT reverse GGATGCTGGCTGGCTGACA 
MLKL KO reverse CCTGCTGCCATCTGAAACGG 
 
2.4.4 Dissection and fixation of tissues for histology 
Mice were euthanised and whole livers were resected with forceps and scissors. 
Tissues were cut into no more than 2 cm pieces, and pieces of livers were fixed in 
10% neutral-buffered formalin (Sigma).  The rest of the tissues were snap-frozen in 
liquid nitrogen for further analysis. Formalin was replaced with 70% ethanol to avoid 
over-fixation before embedding. 
2.4.5 Histological sections 
Formalin-fixed tissues were embedded in paraffin blocks by sequential incubation 
with ethanol, histoclear and paraffin and sliced into thin sections in 4 μm thickness. 
Hematoxylin and eosin (H&E) staining was performed to observe tissue structure. 
Tissue embedding and sectioning were performed by Ms Lorraine Lawrence (NHLI, 




Paraffin sections were dewaxed by sequential treatment with histoclear, 100% 
industrial methylated spirit (IMS), 90% IMS, 75% IMS, 50 % IMS and distilled water. 
For antigen retrieval, heat-induced epitope retrieval with citrate buffer was used for 
Ki-67 and cleaved caspase-3 or Tris-EDTA buffer for Ly6G and γH2AX staining. 
Proteinase K (Promega) 10 μg/mL diluted in TEX buffer was used for demasking 
F4/80 antigen. Tyramide signal amplification (TSA) system (Perkin Elmer) was 
utilised to enhance signals. To detect cell death, terminal deoxynucleotidyl 
transferase dUTP nick end labelling (TUNEL) was performed using ApopTag In situ 
detection kit (Millipore).  
2.4.7 Flow cytometric analysis of liver immune cells 
Livers were processed in PBS with syringe plungers and the cell suspension was 
filtered with 70-μm cell strainer (BD). Cells were washed with PBS and red blood 
cells were removed using RBC lysis buffer (R&D). Cells were incubated with anti-
mouse CD16/CD32 and Fixable Viability Dye eFluor 660 (eBioscience) for 30 min 
prior to incubation with antibodies. Cells were subsequently stained with fluorophore-
coupled antibodies for 1 hour. Cells were fixed with fixation/permeablization 
concentrate (eBioscience) diluted 1:4 in fixation/permeablization diluent 
(eBioscience) until the day of measurement and were washed with PBS shortly 
before measurement. For absolute quantification, 10 μL of 123count eBeads 
(eBioscience) were added to each cell suspension, and cells were measured on 
Fortessa LSR II (BD), followed by analysis using FlowJo 7.6.5 (Tristar). 
2.4.8 Serum analysis 
Blood was withdrawn from the submandibular vein using a lancet and collected into 
Microtainer tube with separation gels (BD). Sampled blood was kept on ice and spun 
to isolate serum. Isolated sera were diluted in 0.9 % (v/w) sodium chloride and 30 μL 
of diluted sera were placed on Reflotron ALT test strip (Roche), which subsequently 




Chapter 3  
3 Results 
3.1 Characterisation of liver-specific HOIP-deficient mice 
3.1.1 Generation of liver-specific HOIP-deficient mice 
Systemic deficiency in the catalytic component of LUBAC, HOIP, in mice causes 
embryonic lethality at mid-gestation (Peltzer et al., 2014). At this stage, the 
developing livers accommodate the precursor of mature hepatocytes and bile duct 
cells, hepatoblasts (Zorn, 2008).  Due to the death of the animals and immaturity of 
liver tissue at this embryonic stage, it is not possible to understand the role of linear 
ubiquitination in the mature liver cells from the study of HOIP-deficient embryos. 
To overcome this issue and specifically investigate the role of linear ubiquitination in 
mature hepatocytes, our laboratory generated mice with liver parenchyma-specific 
deletion of HOIP by crossing Hoipflox mice with transgenic mice expressing Cre 
recombinase under the regulation of the serum albumin promoter (Alb-Cre mice) 
(Postic et al., 1999). Mice deficient for HOIP in the liver, which we named HoipΔhep 
mice, showed a reduction in HOIP expression levels in whole liver cell lysates to 
approximately half of the control mice (Figure 3.1A). This partial penetrance of Cre-
mediated deletion can be explained by the expression of HOIP protein in non-
parenchymal cells. Thus, to specifically analyse the level of HOIP expression in 
hepatocytes, primary hepatocytes were isolated by means of two-step perfusion. In 
contrast to whole liver lysates, hepatocytes isolated from HoipΔhep animals displayed 
a drastic reduction in the level of HOIP protein (Figure 3.1B). HOIP-deficient 
hepatocytes also displayed a slight decline in the levels of the other LUBAC 
components HOIL-1 and SHARPIN, which is in agreement with previous studies 
showing that loss of HOIP destabilises HOIL-1 and SHARPIN in MEFs, keratinocytes 






Figure 3.1 HOIP liver-specific deletion reduces the protein levels of LUBAC components in 
hepatocytes. (A) Whole liver lysates from Hoipflox and HoipΔhep mice at 4 weeks of age were 
immunoblotted for HOIP. (B) Isolated primary hepatocytes from Hoipflox and HoipΔhep mice at 8 weeks 
of age were lysed and immunoblotted for the LUBAC components. These results are representative of 
two independent experiments. 
 
The expression level of HOIP in the murine liver was also examined by 
immunohistochemistry. The staining was performed in collaboration with Professor 
Teresa Marafioti and her team (UCL Cancer Institute). As an internal control, spleen 
sections were stained together with liver sections. The anti-HOIP antibody was 
previously validated for immunohistochemistry in our laboratory (Taraborrelli et al., 
submitted). Whereas HOIP was strongly positive in splenic lymphocytes, 
hepatocytes displayed a faint staining for HOIP. In the liver, HOIP was positive in the 
sinusoids and Kupffer cells (Figure 3.2). Due to the weak staining in hepatocytes, 
there was no obvious difference in staining intensity between Hoipflox and HoipΔhep 
hepatocytes. Together with the results from western blot analysis, these data 
indicated that HOIP is expressed at a lower level in hepatocytes than in leukocytes 


























Figure 3.2 Expression of HOIP in mouse spleen and liver. HOIP immunostaining (brown) was 
performed using anti-murine HOIP antibody and Ventana system (Roche) by Prof Teresa Marafioti's 
laboratory (UCL Cancer Institute). Sections of the spleen from HoipΔhep mice and livers from Hoipflox 
and HoipΔhep mice at 4 weeks of age were employed in the staining. The data is collected from a 
single experiment. 
 
Furthermore, the survival rate of HoipΔhep mice was monitored from their birth to 18 
months of age. HoipΔhep mice were as viable as littermate controls up to 18 month-old 
(Figure 3.3). This result suggests that HOIP ablation in the liver does not affect the 
viability of mice, despite an efficient deletion of HOIP in hepatocytes.  
 
 
Figure 3.3 Survival curves of Hoipflox and HoipΔhep mice. Kaplan-Meier plot of Hoipflox and HoipΔhep 
male mice up to 18 months (Hoipflox n=13 and HoipΔhep  n=15). 
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Hepatic abrogation of the anti-apoptotic protein c-FLIP using Alfp-Cre leads to 
perinatal lethality whilst its deletion by Alb-Cre does not (Piao et al, 2012). Given that 
Alfp-Cre contains an additional enhancer of the Afp gene in its regulatory sequence 
and that deletion by Alfp-Cre occurs earlier than by Alb-Cre, Alfp-Cre could cause a 
more severe phenotype than Alb-Cre (Postic et al., 1999; Kellendonk et al., 2000). 
Consequently, HOIP deletion in hepatocytes using Alfp-Cre could results in 
premature lethality.  To test this, HOIP was deleted in LPCs using Alfp-Cre. For this 
purpose, Hoipflox/+ Alfp-Cre male mice were crossed to Hoipflox/flox female mice. 
Hoipflox/flox Alfp-Cre mice were born approximately at Mendelian ratio and were viable 
at least up to a weaning age (2-3 weeks of age) (Table 3.1). Nevertheless, it is yet to 
be analysed whether they would show impaired survival at a later stage in life. In sum, 
the two Cre driver lines demonstrated that ablation of HOIP in LPCs does not seem 
to affect the viability of mice. 
 






3.1.2 HOIP deficiency in the liver parenchyma results in spontaneous liver 
tumour formation 
Disruption of the NF-κB signalling and cell death pathway in hepatocytes can lead to 
pathogenesis such as hepatitis and fibrosis as well as liver tumourigenesis at a later 
stage of life (Luedde et al., 2007; Betterman et al., 2010; Weber et al., 2010). 
However, these genetic manipulations do not lead to lethality of the animals in most 
of the cases, except for c-FLIP deletion, which causes perinatal death using Alfp-Cre 
(Piao et al., 2012). Although HoipΔhep mice displayed an unaltered survival rate, 
HOIP deletion could be pathogenic at a later stage in life. Therefore, the livers from 
HoipΔhep mice were analysed at 18 months of age.  
Strikingly, the large majority of male HoipΔhep mice at 18 months of age exhibited 
macroscopic nodules in the liver. At this stage, control mice did not show any overt 
aberration in the liver (Figure 3.4A). The size, number and severity of macroscopic 
lesions appearing in HoipΔhep livers were variable.  Four mice out of 13 showed mild 
phenotype with smaller lesions (lesion diameter < 2 mm). Another five mice 
developed a moderate phenotype with multiple lesions and nodules (including 
maximal lesion diameter = 2-5 mm). Lastly, the other three mice suffered from 
severe pathology with large nodules (diameter > 5 mm) together with cystic lesions 
(Figure 3.4A). HCC formation was observed in over a half (5 out of 8) of the HoipΔhep 
animals displaying moderate and severe pathologies (Figure 3.4B, bar graph). The 
other mice that did not have HCC displayed pre-cancerous anisokaryosis or 
inflammatory foci (Figure 3.4B, middle pictures).  
Furthermore, HoipΔhep livers exhibited focal lipid accumulation, which suggests that 
HoipΔhep mice develop steatosis (Figure 3.5). In addition, Sirius red-positive mild 
fibrotic lesions were present at peri-tumour areas (Figure 3.5). Taken together, HOIP 




Figure 3.4 HoipΔhep mice spontaneously develop liver tumours at 18 months of age. (A) 
Macroscopic images of livers from Hoipflox and HoipΔhep mice at 18 months of age. The severity of 
pathology observed in HoipΔhep livers was classified into three levels: mild (5/13), moderate (5/13), and 
severe (3/13). Black and white arrowheads indicate nodules and cysts, respectively.  L: small lesion. 
Fisher's exact test was employed in nodule incidence analysis. (B) H&E sections of livers from Hoipflox 
and HoipΔhep mice at 18 months of age (left panel). I: inflammatory foci, NT: non-tumour, T: tumour. 
The bar graph indicates the most advanced nodule type on the liver which showed moderate and 




Figure 3.5 HoipΔhep mice spontaneously develop steatosis, cystic lesions and fibrotic lesions at 
18 months of age. Macroscopic images of livers from Hoipflox and HoipΔhep mice at 18 months of age. 
Left panel, S: steatotic lesion. Middle panel, C: cystic lesion. Right panel, paraffin-embedded tumour-
bearing HoipΔhep livers were stained with Sirius red. Arrowheads indicate Sirius-red-positive fibrotic 
lesion around the tumour. 
 
3.1.3 Inflammation emerges at early stages of life in HOIP-deficient livers  
The primary cause of liver cancer in human is chronic inflammation (El-serag, 2011). 
Inflammation in several types of cancer promotes the initiation and establishment of 
pro-tumourigenic environment.  I hypothesised that an earlier inflammation 
predisposes HoipΔhep mice to liver tumourigenesis. The presence of liver 
inflammation at an early stage of life in HoipΔhep mice was therefore assessed. 
Firstly, in order to detect the presence of inflammation, the number of hepatic 
leukocytes of Hoipflox and HoipΔhep mice from postnatal day 7 up to 8-9 weeks of age 
was quantified by means of flow cytometry.  Leukocytes were present in the liver at 
equivalent levels in Hoipflox and HoipΔhep mice at postnatal day 7 and 15. However, at 
4 weeks of age, HoipΔhep mice accommodated a significantly higher number of 
leukocytes in the liver as compared to littermate controls (Figure 3.6). At 8-9 weeks 
of age, the leukocyte count of HoipΔhep livers returned to a similar level to that of 
Hoipflox livers. This result indicated that HoipΔhep livers suffered from transient 




Figure 3.6 Quantification of hepatic leukocyte in Hoipflox and HoipΔhep mice at an early stage.  
Livers from Hoipflox and HoipΔhep mice at the indicated ages were processed and stained, and the 
number of CD45+ cells was quantified by flow cytometry. Data were collected from a single experiment 
for Day 7, 15 and 8-9 week time points. The results from the two independent experiments were 
pooled for 4 weeks’ data. Statistics was performed by two-tailed t test. 
 
Figure 3.7 Relative quantification of hepatic cytokine/chemokine transcript levels in Hoipflox and 
HoipΔhep mice at an early stage.  (A) (B) Livers from Hoipflox and HoipΔhep mice at the indicated ages 
were homogenised and mRNAs of indicated genes were relatively quantified by qRT-PCR. Gene 
expression levels in HoipΔhep samples are depicted as fold increase of that of Hoipflox sample. (B) 
Livers were from the animals at 4 weeks of age and mRNAs of indicated genes were relatively 
quantified by qRT-PCR. Data were collected from a single experiment for each time point. The bar 
graphs indicate means and standard error of means. Statistics was performed by two-tailed t test. 
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In agreement with the emergence of inflammation at 4 weeks of age, elevated levels 
of TNF, CCL3 and CXCL1 cytokine/chemokine were detected at this stage (Figure 
3.7A). Intriguingly, the increases in these cytokine/chemokine levels were already 
present at 2 weeks of age, when anatomically inflammation was not yet established 
in HoipΔhep livers.  
A previous study pointed out the contribution of LTβR signalling to the NASH-related 
HCC formation in a CD-HFD model (Wolf et al., 2014). Levels of LTβR ligands, LTβ 
and LIGHT, were therefore evaluated. LTβ transcript was significantly increased, and 
the expression of LIGHT also showed a similar tendency (Figure 3.7B).  Next, the 
level of pro-tumourigenic cytokine IL-6 was assessed, as this is one of the key 
factors to drive liver carcinogenesis (Naugler et al., 2007). However, IL-6 mRNA 
merely showed a marginal increase (Figure 3.7B).  
Coinciding with the exacerbated leukocyte number and cytokine/chemokine levels at 
4 weeks of age, myeloid cell infiltration was present in HoipΔhep livers as detected by 
Ly6G and F4/80 immunostaining. Myeloid cells were accumulated at the site of 
inflammation in HoipΔhep livers (Figure 3.8A). To investigate further which particular 
immune cell subpopulations were recruited to inflamed HoipΔhep livers at 4 weeks of 
age, the different populations of hepatic leukocytes were quantified by flow 
cytometric analysis. F4/80+ monocytes/macrophages, Ly6G+ granulocytes, CD4+ and 
CD8+ T cells and B220+ B cells were accumulated in HoipΔhep livers as compared to 
control livers (Figure 3.8B). Additionally NK and NKT cells were also increased, 
albeit not to a statistically significant degree, in HoipΔhep livers.  This result suggested 
that a wide range of both myeloid and lymphoid compartments appear to be 
indiscriminately recruited to the inflamed HoipΔhep livers and participate in 




Figure 3.8 Characterisation of immune infiltrates at the peak of early inflammation in HoipΔhep 
livers. (A) Liver sections from Hoipflox and HoipΔhep mice at 4 weeks of age were stained for F4/80 
(upper panel) and Ly6G (lower panel), indicated in red. White arrowheads indicate an accumulation of 
corresponding immune cell staining. (B) Liver cells from Hoipflox and HoipΔhep mice were stained and 
the numbers of hepatic immune subpopulations were quantified by flow cytometry. Mo/MF: F4/80+ 
cells, Gr: Ly6G+ cells, CD4 Tc: CD3+ CD4+ cells, CD8 Tc: CD3+CD8+ cells, Bc: B220+ cells, NK: CD3- 
NK1.1+ cells, NKT: CD3+ NK1.1+ cells. Data were collected from a single experiment. Statistics was 
performed by two-tailed t test. 
  
It was reported that the liver undergoes compensatory growth and replenish 
hepatocytes and other types of liver cells by the proliferation of mature hepatocytes 
and liver cell progenitors in response to tissue injury (Miyajima et al., 2014). Despite 
the fact that inflammation underlies chronic liver diseases, it also initiates tissue 
repair by providing damaged tissues with cytokines and growth factors (Karin and 












































proficient and -deficient livers. Indeed, as detected by Ki-67 expression, a higher 
number of proliferating liver cells was observed in HoipΔhep mice at 2-4 weeks of age 
as compared to littermate controls. Therefore, HOIP deletion leads to the initiation of 
liver regeneration, consistent with the presence of inflammation (Figure 3.9). 
 
Figure 3.9 HoipΔhep livers have increased proliferating cells at an early stage.  Liver sections from 
Hoipflox and HoipΔhep mice at the indicated ages were stained for Ki-67. The right graph shows the 
quantification of Ki-67+ cells per optical area (magnification: 400x). Data were collected from a single 
experiment. Statistics was performed by two-tailed t test. 
 
In addition, inflammation can also lead to DNA damage by producing reactive 
oxygen species (ROS) which is associated with inflammation-associated liver 
carcinogenesis (Maeda et al., 2005; Ohnishi et al., 2013). To determine whether 
there is underlying DNA damage response in HOIP-deficient hepatocytes, liver 
sections from 4 week-old HoipΔhep and control mice were stained for phosphorylated 
histone H2AX (γH2AX), a marker for DNA damage.  Intriguingly, HoipΔhep livers 
presented increased γH2AX+ foci, which is suggestive of increased DNA damage in 
HoipΔhep livers (Figure 3.10). In summary, deficiency in HOIP in liver parenchyma 
leads to transient inflammation at early stages of life, accompanied by proliferation of 





Figure 3.10 HoipΔhep livers displayed elevated DNA damage at an early stage.  Liver sections 
from Hoipflox and HoipΔhep mice at 4 weeks of age were stained for phosphorylated H2AX. The right 
graph shows the quantification of γH2AX+ cells per optical area (magnification: 200x). Data were 
collected from a single experiment. Statistics was performed by two-tailed t test. 
3.1.4 HOIP deficiency renders hepatocytes more susceptible to cell death 
which precedes the emergence of inflammation in mice 
In order to quantitatively evaluate the extent of liver damage in HoipΔhep mice, serum 
ALT levels were measured.  ALT is a hepatocyte-specific enzyme which is released 
into the circulation when these cells are damaged. The serum level of ALT from 
HoipΔhep mice showed a mild but significant surge at 2 weeks of age, and it peaked 
at 4 weeks. Yet the value declined between 4 and 8 weeks of age (Figure 3.11). This 
evidence implied that ablation of HOIP in liver parenchyma causes hepatocyte death, 




Figure 3.11 HoipΔhep mice showed higher levels of serum ALT.  Serum ALT levels from Hoipflox and 
HoipΔhep mice at the indicated ages were quantified. Data were collected from multiple independent 
experiments. Statistics was performed by two-tailed t test. 
 
 
Next, to examine the event leading to the emergence of inflammation in HoipΔhep 
livers at 4 weeks of age, pathohistological analyses of HoipΔhep mice from postnatal 
day 1 up to 8 weeks of age were performed. Whilst no aberration in HoipΔhep livers 
was observed at postnatal day 1, apoptotic bodies in HoipΔhep livers were detected at 
postnatal day 7, which became more prevalent at 2 weeks of age as compared to 
controls (Figure 3.12). At 4 weeks of age, the peak of inflammation, we additionally 
observed ductular reactions, proliferation of liver progenitor cells around the veins in 
HoipΔhep livers. Consistent with the observation that inflammation was ameliorated at 
8 weeks of age, apoptotic bodies and ductular reactions were also reduced in 




Figure 3.12 HoipΔhep mice suffer from transient liver damage. Liver sections of Hoipflox and 
HoipΔhep mice at the indicated ages are shown. Black arrowheads indicate apoptotic bodies and white 











Because inflammation followed the occurrence of cell death at postnatal day 7 
onwards and there was no prior aberration detected in HOIP-deficient livers, cell 
death appeared to be the first pathological event in these livers. To better 
understand the cell death observed histologically in HoipΔhep livers, terminal 
deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) and 
immunohistochemistry against cleaved caspase-3 (CC3) were performed to visualise 
and quantify dead and apoptotic cells, respectively. In accordance with the 
histological observation, TUNEL+ cells per area of the liver sections significantly 
increased at 2 weeks, 4 weeks and 8 weeks of age in HoipΔhep livers (Figure 3.13). 
The number of CC3+ apoptotic cells per area was also elevated from postnatal day 7 
up to 8 weeks of age, although they were statistically significant only at 2 weeks of 
age. TUNEL+ and CC3+ cell numbers reached their maximal level at 2 weeks of age, 
which preceded the peak of liver leukocyte count at 4 weeks of age (Figure 3.6). 
HOIP-deficient MEFs display increased caspase-8 and caspase-3 activation in 
response to TNF (Peltzer et al., 2014). To evaluate caspase-8 activation in HOIP-
deleted livers, primary hepatocyte lysates and whole liver lysates were 
immunoblotted for cleaved caspase-8. Primary hepatocytes from HoipΔhep mice at 8-
10 weeks of age displayed activation of caspase-8 as well as caspase-3 cleavage in 
the lysates (Figure 3.14A). Caspase-8 cleavage was detected in HoipΔhep livers as 





Figure 3.13 HoipΔhep mice suffer from increased liver cell death. Liver sections from Hoipflox and 
HoipΔhep mice at the indicated ages were stained for cleaved caspase-3 (CC3) and TUNEL. Stained 
cells per area of the liver sections were quantified and shown in the graphs (left). Data were collected 
from a single experiment. Statistics was performed by two-tailed t test. Cleaved caspase-3 (green in 
the merged picture) and TUNEL staining (red) on Hoipflox and HoipΔhep liver sections at 15 days of age 
are shown in the pictures (right). 
 
 
Figure 3.14 Caspase activation occurs in HOIP-deleted hepatocytes. (A) Isolated primary 
hepatocytes from Hoipflox and HoipΔhep mice at 8-9 weeks of age were lysed two days after plating and 
immunoblotted for cleaved caspase-8 and caspase-3. (B) Whole liver lysates from Hoipflox and 
HoipΔhep mice at 4 weeks of age were immunoblotted for cleaved caspase-8. Data are representative 














































In NEMO-deficient hepatocytes, which also show spontaneous apoptosis in the liver 
and primary culture, levels of anti-apoptotic proteins, cIAP1/2 and c-FLIP, are 
downregulated (Kondylis et al., 2015). Therefore the downregulation of anti-apoptotic 
proteins and/or upregulation of pro-apoptotic proteins could account for caspase 
activation and impaired survival of HOIP-deleted hepatocytes. However, there was 
no obvious difference in the levels of any of the major pro-apoptotic and anti-
apoptotic proteins tested in HOIP-deficient hepatocytes (Figure 3.15). Moreover, Bid 




Figure 3.15 Levels of major pro-apoptotic and anti-apoptotic proteins in HOIP-deleted 
hepatocytes are unaltered. Isolated primary hepatocytes from Hoipflox and HoipΔhep mice were lysed 
















































The biological effect of LUBAC deficiency in the liver parenchyma was evaluated in 
this chapter by creating LPC-specific HOIP knockout mice, HoipΔhep mice. HOIP 
deletion in LPCs, utilising Alb-Cre mice, resulted in an efficient deletion of the protein. 
Although there was no impairment in viability up to 18 months of age, the majority of 
HoipΔhep mice developed macroscopic nodules and lesions in the liver, which 
included malignant tumour at this age. At the perinatal stage, HoipΔhep mice began to 
suffer from hepatocyte apoptosis which is exacerbated up to 2-4 weeks of age. The 
cell death of hepatocytes in HoipΔhep mice was followed by the emergence of 
inflammation. At this stage, leukocyte infiltration and the levels of inflammatory 
mediators were increased, where a wide range of myeloid and lymphoid cells were 
recruited to HoipΔhep liver and engaged in their hepatitis. In line with the aggravated 
cell death and inflammation, liver cell proliferation occurred to compensate the 
damage and increased DNA damage response was detected in HoipΔhep mice. 
HOIP-deficient primary hepatocytes underwent apoptosis characterised by the 
activation of caspase-8 and caspase-3. These results suggest that LUBAC 
deficiency in LPCs is detrimental as it provokes hepatocyte death, notably apoptosis, 






3.2 Dissecting the role of cell death pathways in HOIP deficiency-
induced liver damage  
3.2.1 The role of TNFR1 signalling in HOIP-deficient livers 
As described above, HoipΔhep livers exhibit increased levels of cell death that 
precede the development of hepatitis. It has been shown that LUBAC deficiency 
leads to attenuated gene activation and impaired cell survival in TNFR1 signalling 
(Haas et al., 2009; Gerlach et al., 2011). TNFR1 deletion rescues the cell death and 
inflammatory phenotype in LUBAC-impaired animals (Kumari et al., 2014; Rickard et 
al., 2014; Peltzer et al., 2014).  Therefore it is hypothesised that TNFR1 signalling is 
responsible for the observed hepatocyte death and subsequent hepatitis in HOIP-
deleted livers. To test this hypothesis, HOIP-deficient primary hepatocytes were 
stimulated with TNF and downstream gene-activatory signaling was assessed. As 
expected, IκBα is phosphorylated and subsequently degraded upon TNF stimulation 
in HOIP-proficient hepatocytes whereas phosphorylation and degradation of IκBα 
were markedly attenuated in HOIP-deleted cells (Figure 3.16). Activation of MAP 
kinases, such as ERK and JNK, was unaffected, although HOIP-deficient cells 
displayed high basal ERK activity. 
 
Figure 3.16 TNF-induced canonical NF-κB activation is impaired in HOIP-deficient hepatocytes. 
Isolated primary hepatocytes from Hoipflox and HoipΔhep mice were stimulated with 10 ng/mL TNF for 
the indicated times and cell lysates were immunoblotted for the indicated proteins involved in TNFR1 
signalling. This result is representative of those of three independent experiments. 
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Next, to test whether TNF-induced cell death is affected in HOIP-deficient primary 
hepatocytes, the viability of these cells was assessed. Upon TNF treatment alone, 
cell viability of HOIP-deficient cells was reduced by approximately 30% compared to 
HOIP-proficient cells, indicating that HOIP-deficient hepatocytes are more sensitive 
to TNF-induced cell death, which is akin to the response of HOIP knockout MEFs 
(Figure 3.17; Peltzer et al., 2014).  This effect could be due to loss of NF-κB target 
gene expression as HOIP-deficient hepatocytes have impaired NF-κB activation 
upon TNF stimulation (Figure 3.16). To test this, TNF treatment was combined with a 
translational inhibitor cycloheximide (CHX).  Although co-treatment with CHX 
decreases cell viability in both cells, it does not alter the 30% decrease in viability 
observed between HOIP-deficient versus HOIP-proficient cells (Figure 3.17).  This 
result suggests that HOIP can block TNF-induced cell death in hepatocytes 
independently of its function in activating downstream target genes.  
 
Figure 3.17 HOIP-deficient hepatocytes are sensitised to TNF-induced cell death. Isolated 
primary hepatocytes from Hoipflox and HoipΔhep mice were stimulated with TNF and TNF+CHX for 24 
hours. Relative cell viability was evaluated and shown in the bar graph. The results were collected 
from three independent experiments. The bar graphs indicate means and standard error of means. 
Statistics was performed by two-tailed t test. 
In order to test whether TNFR1 signalling mediates the observed hepatocyte death 
and the subsequent inflammation in HOIP-deficient livers, HoipΔhep mice were 
crossed with systemic TNFR1 knockout mice (Tnfr1KO) (Pfeffer et al., 1993).  
Surprisingly, TNFR1 deletion did not reduce the degree of liver damage in HOIP-




Figure 3.18 Depletion of TNFR1 does not ameliorate liver damage in HoipΔhep mice. Serum ALT 
levels from Hoipflox, HoipΔhep and Tnfr1KO HoipΔhep mice at the indicated ages were quantified. 
Statistics was performed by two-tailed t test. 
 
Figure 3.19 Abrogation of TNFR1 does not reduce cell death in HOIP-deficient livers. (A) 
Cleaved caspase-3 (CC3) and TUNEL-positive cells per optical area were quantified on the liver 
sections from Hoipflox, HoipΔhep and Tnfr1KO HoipΔhep mice at 2 weeks of age. The results were 
collected from a single experiment. Statistics was performed by two-tailed t test. (B) Primary 
hepatocytes from Hoipflox, HoipΔhep and Tnfr1KO HoipΔhep mice at 8-10 weeks of age were lysed and 
































































































In line with the extent of liver damage, the numbers of apoptotic cells and/or dead 
cells per area in HoipΔhep livers also remain unaffected by deletion of TNFR1 (Figure 
3.19A). Furthermore, isolated primary hepatocytes from Tnfr1KO HoipΔhep mice 
displayed similar activation of caspase-8 and caspase-3 to HOIP-deficient cells 
(Figure 3.19B). 
Intriguingly, even though TNFR1 deletion did not rescue the death and caspase 
activation in HOIP-deficient hepatocytes, leukocyte recruitment to HOIP-deficient 
livers was markedly attenuated in Tnfr1KO HoipΔhep mice reaching similar levels to 
HOIP-proficient livers (Figure 3.20, left panel).  Additionally, mRNA levels of TNF 
and CCL3 were strongly decreased in Tnfr1KO HoipΔhep livers (Figure 3.20, right 
panel).  This suggests that TNFR1 ablation significantly alleviates the inflammatory 
phenotype triggered by HOIP deficiency in liver parenchyma.  Since the inflammation 
in HOIP-deficient livers was resolved by TNFR1 deletion, it was hypothesised that 
the subsequent DNA damage caused by inflammation was ameliorated as well. 
Indeed, a significant reduction in the number of γH2AX+ cells in Tnfr1KO HoipΔhep 
livers was observed as compared to HoipΔhep livers (Figure 3.21).  Collectively, these 
results show that, regardless of the TNFR1-independent cell death of HOIP-deficient 
hepatocytes, TNFR1 signalling mediates the inflammation in HOIP-deficient livers. 
 
Figure 3.20 TNFR1 ablation ameliorates inflammation in HOIP-deficient livers. Leukocyte count 
per gramme of the liver in Hoipflox, HoipΔhep and Tnfr1KO HoipΔhep mice at 4 weeks of age were 
quantified (left panel). The levels of Tnf and Ccl3 transcripts were quantified from Hoipflox, HoipΔhep 
and Tnfr1KO HoipΔhep livers by qRT-PCR (right panel). The levels were normalised to those from 
Hoipflox livers. The results for leukocyte count were collected and pooled from two independent 
experiments. The results for cytokine were collected from a single experiment. The bar graphs 


















































Figure 3.21 TNFR1 deletion mitigates DNA damage in HOIP-deficient livers. Liver sections from 
Hoipflox, HoipΔhep and Tnfr1KO HoipΔhep mice at 4 weeks of age were stained for phosphorylated H2AX. 
The right graph shows the quantification of γH2AX+ cells per optical area (magnification: 200x). The 
results were collected from a single experiment. Statistics was performed by two-tailed t test. 
Because TNFR1 ablation did not rescue liver damage in HOIP-deficient livers 
(Figure 3.19), death-inducing extracellular ligands, other than TNFR1 ligands such 
as TNF and LTα, could be responsible for the cell death observed in HOIP-deficient 
livers. Therefore, the sensitivity of HOIP-proficient and -deficient hepatocytes to 
TRAIL and CD95L-induced cell death was evaluated. Treatment with soluble TRAIL 
failed to induce cell death in both cells, with no obvious sensitisation due to HOIP 
deficiency. It was already reported that soluble TRAIL fails to induce cell death in 
primary mouse hepatocytes in previous studies (Walczak et al., 1999; Corazza et al., 
2006). In contrast to TRAIL, CD95L-induced cell death was observed in both HOIP-
proficient and -deficient hepatocytes (Figure 3.22). Interestingly, HOIP-deficient 
hepatocytes were more sensitive to CD95L-induced cell death than HOIP-proficient 
cells (Figure 3.22).  
In addition to death receptor signalling, TLR3 has recently been described to induce 
cell death via recruiting the cell death-inducing signalling platform (Feoktistova et al., 
2011). In line, HOIP-deficient hepatocytes are also sensitised to cell death induced 





Figure 3.22 HOIP-deficient hepatocytes are more sensitive to CD95L- and Poly(I:C)-induced 
cell death. Primary hepatocytes from Hoipflox and HoipΔhep mice were treated with 1 μg/mL TRAIL, 
CD95L and poly(I:C) for 24 hours, and relative cell viability was quantified. The results were collected 
from three independent experiments. The bar graphs indicate means and standard error of means. 
Statistics was performed by two-tailed t test. 
3.2.2 Formation of cell death-inducing signalling complex 
As hepatocyte death occurs to a similar degree in HoipΔhep and Tnfr1KO HoipΔhep 
livers, they may share the same molecular mechanism underlying hepatocyte death. 
Activated caspase-8 is a major player in apoptosis and its activation is mediated by a 
cell-death-inducing platform containing FADD, RIPK1 and caspase-8, formation of 
which can be triggered by various exogenous stimuli (Tenev et al., 2011; Feoktistova 
et al., 2011; Conrad et al., 2016). As both HoipΔhep and Tnfr1KO HoipΔhep hepatocytes 
displayed caspase-8 activation (Figure 3.19B), the presence of a FADD-containing 
complex in a basal condition was analysed in primary hepatocytes from HoipΔhep and 
Tnfr1KO HoipΔhep mice. Of note, these experiments were performed in the presence 
of zVAD in order to stabilize a FADD-associated signalling complex. In HOIP-
deficient primary hepatocytes, regardless of the presence of TNFR1, strikingly 
elevated levels of caspase-8, c-FLIP and RIPK1 were found to be associated with 
FADD, independently of the presence of TNFR1 (Figure 3.23A).  In the FADD-
associated cell death-inducing complex, an increased amount of cleaved caspase-8 
was detected, indicating that caspase-8 is activated therein. Consistent with 
caspase-8 cleavage, its modulator c-FLIPL was also found to be cleaved, 
presumably by associated activated caspase-8. Furthermore, ubiquitinated form of 
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both cleaved caspase-8 and RIPK1 are found in the complex (Figure 3.23A). Thus, 
HOIP deficiency results in spontaneous formation of a FADD-RIPK1-caspase-8-c-
FLIP death-inducing signalling platform, independently of TNFR1 signalling, which 
could be responsible for activation of caspase-8 and apoptosis in HOIP-deficient 
hepatocytes. 
Since LUBAC suppresses TNF-induced cell death independently of its gene-
activatory role (Figure 3.17), it was tested whether such cell death-inducing platform 
is formed independently of HOIP's gene-activatory capacity as well. Therefore, 
primary hepatocytes were treated with CHX to abrogate protein translation and 
subsequently the FADD-associated complex was immunoprecipitated. Treatment 
with CHX did not increase the complex formation in HOIP-proficient cells to the level 
of HOIP-deficient cells (Figure 3.23B). This result suggests that the FADD-RIPK1-
caspase-8 complex formation was not triggered by impaired gene activation. 
 
Figure 3.23 HOIP-deficient hepatocytes display increased apoptosis-inducing signalling 
complex formation independently of TNFR1 signalling and loss of gene activation. (A) Primary 
hepatocytes from Hoipflox (F), HoipΔhep (Δ) and Tnfr1KO HoipΔhep mice (TΔ) were treated with zVAD for 
24 hours and subjected to immunoprecipitation using anti-FADD antibody. (B) Primary hepatocytes 
from Hoipflox (F) and HoipΔhep (Δ) were treated with zVAD for 24 hours in the presence or absence of 
CHX for 24 hours and FADD was subsequently immunoprecipitated from cell lysates. These results 
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RIPK1 is the central regulator for the assembly of a FADD-RIPK1-caspase-8 death-
inducing complex (Conrad et al., 2016). Previous studies have demonstrated that the 
kinase activity of RIPK1 is required for this complex formation and subsequent cell 
death (Tenev et al., 2011). Therefore, it was analysed whether the FADD-RIPK1-
caspase-8-containing complex spontaneously accumulating in HOIP-deficient cells 
was dependent on the RIPK1 kinase activity. To do so, the FADD-RIPK1-caspase-8 
complex was immunoprecipitated from RIPK1 inhibitor Nec-1s- and zVAD-treated 
primary hepatocytes isolated from Hoipflox and HoipΔhep mice. Although treatment 
with Nec-1s reduced the complex formation in HOIP-proficient hepatocytes, Nec-1s 
did not largely affect that of HOIP-deficient hepatocytes (Figure 3.24). This result 
demonstrates that the enhanced formation of the death-inducing complex in the 
absence of HOIP cannot be inhibited by Nec-1s, whilst its basal formation in HOIP-
proficient cells can be. 
 
Figure 3.24 Apoptosis-inducing signalling complex in HOIP-deficient hepatocytes is 
uninhibited by treatment with the allosteric RIPK1 inhibitor Nec-1s. Primary hepatocytes from 
Hoipflox and HoipΔhep mice were treated with zVAD for 24 hours in the presence or absence of Nec-1s 
(Nec, added to culture 1 hour before zVAD addition) and were subjected to immunoprecipitation using 
anti-FADD antibody. Lysates and precipitates were immunoblotted for the indicated proteins. This 
result is representative of those of three independent experiments. 
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3.2.3 Genetic deletion of MLKL and caspase-8 affects the early pathology of 
the HOIP-deficient livers 
Caspase-8-mediated apoptosis is attributed to carcinogenesis in TAK1-deficient 
livers (Vucur et al., 2013). Therefore, inhibition of apoptosis by deleting caspase-8 
gene could prevent liver damage and inflammation in HOIP-deficient livers. In line, 
heterozygosity of caspase-8 prevents hepatocarcinogenesis in liver-specific NEMO-
deficient mice (NemoLPC-KO mice) (Liedtke et al., 2011). To investigate whether early 
liver damage in HoipΔhep mice is mitigated by halving the gene dosage of caspase-8, 
HoipΔhep mice were crossed to systemic caspase-8 heterozygous mice (Casp8+/-, 
Casp8HET) as systemic knockout of caspase-8 is embryonically lethal (Kang et al., 
2004). Serum ALT values of Casp8HET HoipΔhep mice were comparable to those of 
HoipΔhep mice (Figure 3.25), suggesting that that deletion of one allele of caspase-8 
is not sufficient to alleviate the early liver damage in HoipΔhep mice. 
 
Figure 3.25 Caspase-8 heterozygosity does not alleviate liver damage of HoipΔhep mice. Serum 
ALT values from mice at 4 weeks of age with the indicated genotypes are shown in the graph. The 
data is collected and pooled from two independent experiments. 
Although caspase-8 heterozygosity did not decrease ALT values, a reduction in the 
numbers of CC3+ and TUNEL+ cells per area was observed (Figure 3.26). This result 
suggests that the remaining apoptosis is sufficient to trigger liver damage and that an 
additional apoptosis-independent process is responsible for the liver damage in 



















Figure 3.26 Caspase-8 heterozygosity reduces apoptosis in HoipΔhep livers. The numbers of 
CC3+ cells and TUNEL+ cells per area in livers from HoipΔhep, Casp8HET Hoipflox and Casp8HET HoipΔhep 
mice at 2 weeks of age are shown in the graphs. The data is collected from a single experiment. 
 
Despite the decrease in apoptotic cells in the liver, the percentage of hepatic 
leukocytes in Casp8HET HoipΔhep mice was elevated to an equivalent extent as 
HoipΔhep mice at the peak of inflammation (Figure 3.27). This result indicates that 
inflammation was not ameliorated by partial loss of caspase-8. 
 
 
Figure 3.27 Caspase-8 heterozygosity does not ameliorate leukocyte infiltration into HoipΔhep 
livers. Percentage of leukocytes present in the livers of Hoipflox, HoipΔhep, Casp8HET Hoipflox and 
Casp8HET HoipΔhep mice at 4 weeks of age are plotted in the graph. The data is collected and pooled 




































































Heterozygosity of caspase-8 did not rescue liver damage evaluated by serum ALT in 
HOIP-deficient livers, whereas TUNEL+ or CC3+ cells therein were reduced, which 
suggests the presence of non-apoptotic cell death. Blockade of caspase-8 activity is 
a trigger to induce RIPK3/MLKL-dependent necroptosis (Conrad et al., 2016). Thus, 
heterozygosity of caspase-8 could also sensitise hepatocytes to necroptosis by 
lowering the amount of caspase-8 in cells. It has been shown that necroptotic cells 
can be negative for TUNEL (Carneiro et al., 2009), and therefore TUNEL performed 
in HOIP-deficient livers could have overlooked the presence of necroptotic cells 
therein.  
Pathology triggered by SHARPIN deficiency was completely reverted by RIPK3 
deletion and caspase-8 heterozygosity (Rickard et al., 2014), indicating the crucial 
role of RIPK3 in the cpdm phenotype. However, RIPK3 deletion in HOIP-floxed 
animals cannot be performed by conventional crossings due to the genetic proximity 
of Ripk3 and Hoip loci (Peltzer et al., 2014). It has been shown that the embryonic 
lethality of caspase-8 knockout mice can be circumvented by co-deleting necroptosis 
executer MLKL, although the double knockout mice develop lymphadenopathy at a 
few months of age (Etemadi et al., 2015).  Therefore, Casp8HET HoipΔhep mice were 
crossed to MLKL knockout (MlklKO) mice to evaluate the contribution of necroptosis 
in the phenotype. Deletion of MLKL in addition to caspase-8 heterozygosity did not 
reduce ALT values in HoipΔhep mice (Figure 3.28).  This result suggests that one 
allele of caspase-8 is sufficient to initiate apoptosis in MlklKO Casp8HET HoipΔhep livers, 
as apoptotic bodies are present in these livers (Figure 3.28).  
Strikingly, MlklKO Casp8KO HoipΔhep mice showed serum ALT values comparable to 
those of Hoipflox mice, indicating that the co-deletion of MLKL and caspase-8 
completely prevents liver damage induced by HOIP deficiency (Figure 3.28). 






Figure 3.28 MLKL deletion and caspase-8 heterozygosity do not ameliorate liver damage in 
HoipΔhep mice, whereas co-ablation of MLKL and caspase-8 rescues it. Serum ALT levels and 
liver histology of MlklKO Casp8HET HoipΔhep and MlklKO Casp8KO HoipΔhep mice at 4 weeks of age are 
presented. Black arrowheads in the H&E-stained sections indicate apoptotic bodies. The data is 






















In this subchapter, the contributions of the TNFR1 signalling, as well as the 
involvement of apoptotic and necroptotic pathways to the pathogenesis of HoipΔhep 
mice were examined in order to decipher the molecular mechanisms causing liver 
upon HOIP deficiency in LPCs. In summary, HOIP-deficient hepatocytes were 
sensitised to TNF-induced cell death and displayed impaired NF-κB activation in 
response to TNF. Unexpectedly, systemic TNFR1 ablation did not affect the liver 
damage and cell death. Double TNFR1- and HOIP-deficient hepatocytes underwent 
apoptosis via caspase-8 and caspase-3 activation to a similar extent to HOIP-
deficient cells. However, Tnfr1KO HoipΔhep exhibited much less severe inflammation 
as compared to HoipΔhep mice. 
In addition, the involvement of apoptotic and necroptotic pathways in the observed 
phenotype was assessed. Halving the gene dosage of caspase-8 did not largely 
ameliorate liver damage or inflammation. Also, depletion of the necroptosis executer 
MLKL on top of heterozygosity of caspase-8 also failed to mitigate liver damage. By 
contrast, complete deletion of both caspase-8 and MLKL abolished liver damage in 
HoipΔhep mice. Taken together, these results illustrated that TNFR1-independent but 
caspase-8 dependent apoptosis plays a central role in the development of liver 






Chronic inflammation predisposes the liver to cancer (El-serag, 2011). Disturbance 
of NF-κB signalling and/or cell death pathway may result in severe pathology in 
epithelial tissues (Pasparakis, 2012). Dysregulation of TNFR1 signalling and NF-κB 
signalling components has been associated with liver pathogenesis and 
tumourigenesis in several mouse models (Luedde et al., 2007; Bettermann et al., 
2010; Inokuchi et al., 2010; Nikolaou et al., 2012; Kondylis et al., 2015). However, 
the role of LUBAC and linear ubiquitination in hepatic cells has been poorly 
understood. In this thesis, mice specifically lacking HOIP in liver parenchyma were 
generated and the physiological role of LUBAC in hepatocytes was examined. 
LUBAC deficiency in liver parenchymal cells leads to hepatocyte apoptosis and 
inflammation in the liver at an earlier stage and promotes tumour formation. The 
mechanisms by which LUBAC deficiency results in cell death, hepatitis and eventual 
oncogenesis is discussed in this chapter. 
 
4.1 Impact of HOIP deletion in liver parenchyma 
4.1.1 Cre expression, loss of HOIP and cell death 
Alb-Cre expression starts around embryonic day 14.5, and Cre gradually excises 
loxP-flanked genomic DNA until 6-7 weeks of age, when gene deletion is completed 
in approximately 90% of the alleles (Postic et al, 1999; Weisend et al, 2009). 
Embryonic livers at mid-gestation accommodate hepatoblasts and a large amount of 
hematopoietic progenitor cells. As hepatoblasts differentiate into mature hepatocytes 
during late gestation, hepatocytes begin to express albumin. In correlation with the 
increased level of serum albumin protein, Cre proteins are expressed in hepatocytes 
and excise loxP-flanked DNA. 
In line with these reports, Alb-Cre-mediated HOIP deletion was efficiently executed 
in hepatocytes by 7-9 weeks of age in HoipΔhep mice. Due to the low sensitivity of 
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HOIP antibody in immunohistochemistry it was not possible to assess which 
percentages of hepatocytes are devoid of HOIP at perinatal stages of the liver. 
Moreover, it has been unsuccessful to isolate hepatocytes from younger mice due to 
smaller sizes of the organ and vessels. Based on the fact that deletion mediated by 
Alb-Cre lasts from late gestation to 6 weeks of age, it appears that HOIP is deleted 
during this period.  
A sharp rise in cell death was observed between 1-2 weeks of age, implying the 
induction of cell death by unknown mechanisms may be exacerbated during this 
period. Since there is a delay in achieving depletion of a target protein after its gene 
deletion, depending on the stability of the protein, Hoip gene deletion by Alb-Cre 
seems to take place perinatally, which is in line with the literature on Alb-Cre (Postic 
et al, 1999; Weisend et al, 2009). Figure 4.1 represents a modelling of the kinetics of 
HOIP protein deletion and percentage of dead cells.  The number of dead cells 
should be proportional to the derivative of the number of dead cells, presumably with 
a certain delay in time. As deletion rate goes up in an accelerating manner, the dead 
cells increase. On the other hand, when deletion rate slows down, fewer cells 
undergo cell death. This simulation fits well the kinetics of dead cells per area 
observed in this study. 
 
 
Figure 4.1 Model of kinetics of HOIP deletion and dead cell number in HoipΔhep livers 
 
However, the steep surge in ALT values is only observed in 2-4 week-old mice, 
which follows the peak of dead cells per area in the liver at 2 weeks of age. 
Measured ALT is the protein that leaks out of damaged hepatocytes. Thus, these 
factors would need to be considered: (i) biological half-life of ALT in the circulation, 
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and (ii) liver size and growth during this period. Because ALT could remain in the 
blood for a certain time after its release, this might cause a delay in the increase in 
ALT values. Finally, the size of the liver significantly expands during the first month 
of life in mice as they rapidly gain body weight. The drastic increase in the liver size 
might account for the delay in the surge of the total number of dead cells as 
compared to the number of the dead cells per area. 
In the case of c-FLIP deletion in the liver, the two Cre drivers targeting LPCs has 
been shown to give rise to distinct phenotypes. While deletion with Alb-Cre causes 
only liver damage with elevated ALT, modification with Alfp-Cre confers perinatal 
lethality to mice (Piao et al., 2012). Scientists who established Alfp-Cre mice noticed 
that albumin expression was also regulated by an enhancer of alpha-fetoprotein 
(Afp) genes, which is located next to Alb gene (Kellendonk et al., 2000). By 
combining the Alb gene regulator with Afp gene enhancer, Alfp-Cre achieves an 
efficient induction of Cre from embryonic day 10.5, which is earlier than the initiation 
of Cre expression by Alb-cre. It is not entirely clear when Alfp-Cre achieves full 
penetrance of gene deletion during development, but c-FLIP deletion with Alfp-Cre 
demonstrated an efficient depletion of the protein already at postnatal day 1 (Piao et 
al., 2012). Although an earlier efficient deletion of HOIP at the perinatal stage is 
expected with Alfp-Cre, Hoipflox/flox Alfp-Cre mice were not lethal up to a weaning age.  
It will be intriguing to investigate whether there is any difference between phenotypes 
caused by gene deletion with Alb-Cre and Alfp-Cre at later stages of life. 
4.1.2 Cell death precedes inflammation 
The emergence of apoptotic bodies in HoipΔhep mice was observed as early as 
postnatal day 7, which clearly precedes that of inflammation at 4 weeks of age. Initial 
apoptosis appears to trigger an early induction of cytokines at 2 weeks of age. 
Histologically, at 2 weeks of age, some apoptotic cells are approached by immune 
cells (Figure 3.12), which implies that leukocytes react to the cytokines and DAMPs 
produced by dead cells in HOIP-deficient livers. This process seems exacerbated 
around 4 weeks of age, when a wide range of immune cells is recruited to the site of 
inflammation in HOIP-deficient livers. Furthermore, the apparent resolution of 
inflammation coincided with the sharp decline in the number of dead cells in the liver. 
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Given that cell death due to loss of LUBAC is the primary driver of inflammation 
therein, it is highly likely that inflammation is ameliorated because its source, cell 
death, is reduced.  
This observation is in line with accumulating evidence indicating that cell death is a 
driver of inflammation in various in-vitro and in-vivo studies. For instance, in LPC-
specific truncated CYLD knock-in mice, the first abnormality detected is increased 
cell death from day 10 onwards, which precedes the induction of Tnf mRNA and 
immune cell activation at day 35 (Nikolaou et al., 2012). Thus, it appears that cell 
death drives production of inflammatory cytokines, which in turn renders cells prone 
to undergo cell death further. This is in accordance with the notion that regulated cell 
death participates in the initiation and amplification of inflammation (Pasparakis and 
Vandenabeele, 2015). 
 
4.2 Tumourigenic process 
4.2.1 Pathological aspects 
The initial liver cell death in HoipΔhep mice at postnatal day 7 was not accompanied 
by an inflammatory feature at all. The initial aberration observed, cell death, is 
reminiscent of a histological feature of patients suffering from drug-induced liver 
injury (DILI). The most common cause of DILI is an overdose of paracetamol 
(acetaminophen, N-acetyl-para-aminophenol, or APAP) due to its availability and 
popularity (Tajiri and Shimizu, 2008). However, in contrast to the excessive 
apoptosis in HOIP-deficient livers, a major characteristic of DILI is hepatocyte 
necrosis. The mechanism by which APAP induces cell death is not entirely clear. 
APAP is converted to a reactive metabolite (N-acetyl-p-benzoquinone imine, NAP-
QI) in hepatocytes. Upon APAP overdose, accumulated NAP-QI depletes the 
reducing capacity of glutathione. Currently the only effective intervention for DILI is 
the antioxidant N-acetylcysteine (NAC), which promotes the recovery of the level of 
glutathione in the liver after APAP overdose. NAC counteracts the oxidising action of 
NAP-QI toward glutathione to facilitate its regeneration. ROS production is 
associated with carcinogenesis as it causes immune activation and provokes DNA 
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damage in stromal cells (Ohnishi et al., 2013). In livers devoid of IKK2 or NEMO, a 
reduced level of superoxide dismutases (SODs), which are enzymes quenching 
ROS, seems to exacerbate inflammation (Maeda et al, 2005; Vlantis et al, 2015). 
The expression level of SODs is upregulated by constitutive activation of canonical 
NF-κB by expressing an active form of IKK2 (Vlantis et al., 2015). Therefore, it will be 
interesting to pursue whether liver damage and tumourigenesis triggered by HOIP 
deletion would be ameliorated by treatment with antioxidants or upregulation of 
SODs. 
HOIP-deficient livers seem to lack a robust fibrogenesis, which is often seen in 
human patients suffering from liver cancer and NEMO or TAK1 deficiency in murine 
livers (Luedde et al., 2007; Betterman et al., 2010; El-serag, 2011). However, it has 
been reported that HCV-associated cancer can evolve without cirrhosis (De Mitri et 
al., 1995).  Also there are increasing numbers of liver cancer patients without a prior 
history of liver cirrhosis, which appears to be linked to NAFLD, particularly in the 
Western world (Rahman et al., 2013).  Insulin resistance is linked to fat accumulation 
in the liver. Excessive visceral fat deposition promotes the release of pro-
inflammatory cytokines. Hyperglycemia caused by insulin resistance leads to 
increased oxidative stress which also promotes inflammation. Interestingly, in a 
mouse model, DEN and HFD-induced hepatocarcinogenesis is promoted by 
inflammatory cytokines IL-6 and TNF (Park et al., 2010). 
As the accumulation of lipid droplets was observed in HOIP-deficient livers at 18 
months of age, it is reasonable to speculate that HoipΔhep mice suffer from NAFLD-
related symptoms. The mechanism as to how cell death-driven inflammation driven 
by cell death leads to accumulation of fatty acids in hepatocytes needs to be 
addressed. In a NASH mouse model employing CD-HFD, C57BL/6 mice develop 
CD8+ T cell- and NKT cell-driven steatohepatitis (Wolf et al., 2014). Deletion of the 
TNF superfamily member LIGHT or its receptor LTβR prevents the development of 
steatohepatitis and HCC in mice. LIGHT effectively upregulates fatty acid intake in 
hepatocytes (Wolf et al., 2014), and LIGHT-mediated dyslipidemia is dependent on 
LTβR (James et al., 2007). In humans, serum LIGHT is increased in NAFLD patients 
(Otterdal et al., 2015).  Light mRNA level has a tendency to increase at the peak of 
inflammation in HoipΔhep livers. Moreover, the other LTβR ligand LTβ was highly 
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upregulated in HoipΔhep livers. Therefore, it would be tempting to investigate the role 
of LTβR and its ligands in HoipΔhep livers. 
There is no evidence, to date, that loss of LUBAC occurs in human patients suffering 
from liver diseases. In mouse models of NASH, methionine- and choline-deficient 
diet (MCD) induces downregulation of LUBAC components and impairment in 
LUBAC formation (Matsunaga et al., 2015). Yet it remains unsolved whether LUBAC 
downregulation is responsible for MCD-induced liver damage and steatohepatitis. It 
will be intriguing to investigate whether hepatotropic virus carriers, ASH, NASH and 
HCC patients displays any change in the protein levels of LUBAC components. If this 
is the case, sustaining LUBAC function might be a promising strategy for a novel 
therapy in such patients. 
4.2.2 DNA damage and selection 
After hepatitis flares in HoipΔhep mice at 4 weeks of age, the inflammation is 
ameliorated, suggesting that inflammation is transient and not sustained. Is this mere 
transient inflammation sufficient to account for the eventual tumourigenesis? In the  
case of a chemically-induced liver cancer model, a single injection of carcinogen 
DEN in C57BL/6 mice at early age induces liver cancer later in life (Maeda et al., 
2005), which means that mutagenesis at an early stage is sufficient to trigger 
carcinogenesis even without chronic inflammation. According to the ‘Big Bang’ model 
of cancer evolution, most of the intra-tumour heterogeneity is derived from early 
genetic alteration, rather than later clonal expansions (Sottoriva et al., 2015). This 
model also indicates that some tumour subclones can acquire malignant 
characteristics at a very early stage of carcinogenesis. If this model applies to 
HoipΔhep livers, their early transient inflammation can be a decisive factor in 
determining the mutagenic signature of hepatocytes which later give rise to a tumour. 
An increased DNA damage response was detected in HoipΔhep livers at the peak of 
inflammation (Figure 3.10), which could explain, at least in part, the process of 
oncogenesis therein. The extent of DNA damage appears to be correlated with that 
of inflammation since Tnrf1KO HoipΔhep mice had less γH2AX+ cells with reduced 
inflammation as compared to HoipΔhep mice (Figure 3.21). It will be interesting to 
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know if this decreased inflammation correlates with less severe tumourigenesis at a 
later stage. 
It is still unclear what genes are affected and mutated in HoipΔhep mice. It certainly is 
an interesting question to test whether HoipΔhep livers develop well-known oncogenic 
mutations in their genome, for instance Tp53 and Ctnnb1, at different ages until 
tumours arise in HoipΔhep mice. Nodules from Tak1LPC-KO and NemoLPC-KO mice 
exhibited upregulation of proliferation and cell cycle genes (Betterman et al., 2010). 
The rate of gene alteration in Tak1LPC-KO livers is clearly correlated with the degree of 
apoptosis and inflammation, as caspase-8 deletion abolishes most of it (Vucur et al., 
2013).   
Hepatocytes devoid of HOIP are prone to undergo cell death. Despite the efficient 
deletion of HOIP, the vast majority of HOIP-deficient hepatocytes are still alive. This 
means that a substantial portion of HOIP-deficient hepatocytes are able to survive 
the environment. It is also possible that they adapted to the change in LUBAC levels 
by upregulating some pro-survival factors unexamined here, which in turn could 
contribute to oncogenesis. 
4.2.3 Pro-tumourigenic signalling pathways 
IL-6 is one of the most prominent pro-tumourigenic cytokines, notably in liver cancer 
(He et al., 2010). IL-6 activates transcription factor STAT3, which is a transcription 
activator of pro-survival genes and frequently mutated in human cancer. In murine 
liver cancer models, IL-6 promotes chemically-induced liver carcinogenesis and, in 
preneoplastic lesions, liver cancer progenitor cells grow depending on autocrine IL-6 
signalling (Naugler et al., 2007; He et al., 2013). At the peak of early inflammation in 
HoipΔhep mice, no significant increase in the level of Il6 mRNA was observed (Figure 
3.7). However, the future work will investigate the contribution of IL-6 in 
tumourigenesis in HoipΔhep mice by evaluating the level of IL-6 at 18 months of age 
at which the majority of the animals developed nodules. In addition, STAT3 
activation in the pre-cancerous stage will be also examined to determine whether 
STAT3 activation is involved in the oncogenesis. 
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Disruption of NF-κB signalling components in LPCs often results in hyperactivation of 
JNK (Vucur et al, 2013; Nikolaou et al, 2012; Betterman et al., 2010). Deletion of 
JNK1 diminishes the susceptibility of Ikk2Δhep mice to chemically-induced 
carcinogenesis (Sakurai et al., 2006). Furthermore, abrogation of TAK1 and NEMO 
in LPCs also leads to oncogenesis with JNK hyperactivation (Luedde et al., 2007; 
Betterman et al., 2010; Inokuchi et al., 2010). JNK activation in Ikk2Δhep and 
NemoLPC-KO livers is reduced by treatment with an antioxidant, suggesting JNK 
activation is mediated by ROS in these contexts.  In NemoLPC-KO livers, the JNK 
pathway appears to be activated by TAK1. Aberrant TAK1 activation is also present 
in LPC-specific truncated CYLD knock-in livers, where CYLD truncation causes 
accumulation of Lys63-linked ubiquitin chains on TAK1. In fact, ablation of TAK1 in 
the CYLD-mutant livers results in amelioration of periportal cell death and fibrosis, 
although LPC-specific CYLD-mutant TAK1-deficient mice suffer from carcinogenesis, 
similar to Tak1LPC-KO mice (Nikolaou et al., 2012). Thus, the JNK pathway is engaged 
in the promotion of inflammation, and compensatory proliferation of hepatocytes. Yet, 
how NF-κB inhibition leads to JNK activation is not entirely clear. In HOIP-deficient 
hepatocytes, the basal level of JNK activation in primary hepatocytes is unaltered 
(Figure 3.16).  Therefore, analysis of the TAK1-JNK signalling in the inflamed 
HoipΔhep livers will be needed to clarify whether the TAK1-JNK axis promotes cell 
death, inflammation and regeneration of LUBAC-deficient hepatocytes. 
Hyperactivation of the canonical Wnt pathway is one of the common characteristics 
of human liver cancer by mutation of signalling components, such as β-catenin and 
Axin (Kan et al., 2013). The role of LUBAC in Wnt signalling is yet unclear. Only a 
few studies to date investigated its role and claimed that LUBAC has a suppressive 
role in Wnt signalling. OTULIN interacts with Wnt signalling adaptor DVL2 and 
augments Wnt signalling output (Rivkin et al., 2013). By contrast, overexpression of 
HOIP and HOIL-1 suppresses Wnt signalling. OTULIN counteracts LUBAC to 
promote the signalling via binding to the PUB domain of HOIP (Takiuchi et al., 2014).  
As the  Wnt pathway is crucial for determining liver zonation (Planas-Paz et al., 
2016), disruption of Wnt pathway by LUBAC deficiency could impair liver 




4.3 Role of TNFR1 signalling 
TNF-induced cell death is causative for the inflammatory phenotype of cpdm mice 
(Gerlach et al., 2011; Rickard et al., 2014; Kumari et al., 2014). Increased liver cell 
apoptosis in cpdm mice is reduced by genetic deletion of TNFR1 in the whole body 
(Kumari et al., 2014). Unexpectedly however, apoptosis and TUNEL-positive cell 
death in HOIP-deficient livers are independent of the presence of TNFR1.  
In the case of epidermal keratinocytes in cpdm mice, TNFR1 deletion in the 
epidermis is sufficient to inhibit dermatitis (Kumari et al., 2014). As keratinocytes are 
a potent source of TNF, cell-autonomous TNF-TNFR1 pathway appears to be 
causative for keratinocyte death and skin inflammation in cpdm mice. In contrast, 
TNFR1 ablation did not prevent basal cell death in HOIP-deficient hepatocytes 
although, in vitro, they were sensitised to TNF-induced cell death. This result clearly 
indicates that TNF does not account for hepatocyte death in vivo upon HOIP deletion. 
Moreover, an increased level of TNF does not seem to amplify the death of 
hepatocytes, since there is no difference in serum ALT values between HoipΔhep 
mice and Tnfr1KO HoipΔhep mice whereas hepatic TNF level was much less in the 
latter.  It remains enigmatic whether the death of LUBAC-deficient hepatocytes 
requires some ligands, or whether it occurs spontaneously. 
Interestingly, despite the fact that TNFR1 was not involved in hepatocyte death, 
TNFR1 deletion ameliorated inflammation of HOIP-deficient livers, as characterised 
by the decrease in leukocyte number and cytokine production. Since Tnfr1KO 
HoipΔhep mice have a similar degree of cell death, the process after cell death such 
as the recognition of cell death, reaction to dead cells and/or amplification of 
inflammation must be hampered by systemic abrogation of TNFR1. These processes 
are predominantly mediated by non-parenchymal cells. For instance, TNFR1 
signalling is involved in activation of APCs in response to inflammatory cytokines 
(Calzascia et al., 2007). TNF is a potent activator of myeloid cells and TNF inhibits 
the expression of arginase, which plays an anti-inflammatory role by depriving 
immune cells of their nutrient, arginine. Therefore, pro-inflammatory functions of 
immune cells could be hampered by TNFR1 abrogation. 
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In addition to immune cells, it was considered that TNFR1 signalling in non-
parenchymal and non-hematopoietic cells could participate in inflammation in 
NemoLPC-KO mice (Ehlken et al., 2015).  For example, recruitment of leukocytes from 
blood is regulated by immune cells and sinusoidal endothelial cells (Shetty et al., 
2008). Endothelial cells play a crucial role in retaining immune cells in the tissue by 
expressing adhesion molecules. Notably ICAM-1 and VCAM-1 are adhesion 
molecules upregulated by TNF-mediated NF-κB activation (Pober and Sessa, 2007). 
Some chemokines recruiting lymphocytes, notably CCR5 ligands CCL3-5, are highly 
expressed in human liver endothelial cells (Shetty et al., 2008). These chemokines 
are induced by NF-κB signalling and also secreted from hepatocytes and hepatic 
stellate cells, which can together exacerbate inflammation. 
Moreover, TNF is not the only ligand for TNFR1. Another ligand for TNFR1 
characterised to date is LTα. LTα activates NF-κB signalling and induce cell death in 
HOIP-deficient cells, just as TNF (Peltzer et al., 2014). TNFR1 ablation rescues the 
lethality of HOIP-deficient mouse embryos to a larger degree than TNF knockout. 
Moreover, TNF knockout in the whole body does not mitigate cell death, 
inflammation and carcinogenesis in NemoLPC-KO livers (Ehlken et al., 2015), whereas 
systemic TNFR1 knockout does (Cubero et al., 2014).  Therefore, non-TNF TNFR1 
ligand, presumably LTα, may also be involved in the pathogenesis. 
 
4.4 How does LUBAC deficiency kill hepatocytes? 
Since TNFR1 abrogation in HoipΔhep mice did not alleviate the aberrant cell death in 
the liver, TNFR1-independent pathways are responsible for the death induction. 
Homozygous caspase-8 deletion completely prevented the liver damage in MlklKO 
HoipΔhep (Figure 3.28), whereas MLKL did not rescue it, which suggests caspase-8 
dependent apoptosis is the primary cause of liver damage in HoipΔhep livers. In this 
subchapter, I will discuss which pathways might be involved in activation of caspase-




In a search for the molecular mechanism of activation of caspase-8 in HoipΔhep livers, 
the FADD-RIPK1-caspase-8 complex formation was noticed, and this formation was 
independent of the defect in gene activation. Several studies demonstrated that the 
RIPK1 kinase activity is required for the formation of the FADD-RIPK1-caspase-8 
complex, where cIAP1/2 depletion, TAK1 inhibition and NEMO depletion induce such 
complex (Tenev et al., 2011; Dondelinger et al., 2013; Dondelinger et al., 2015;  
Conrad et al., 2016). By contrast, upon TLR3 activation and cIAP depletion, the 
RIPK1 kinase activity is dispensable to induce cell death, whereas RIPK1 
knockdown prevents cell death (Feoktistova et al., 2011). This study indicates that 
involvement of the kinase activity of RIPK1 in activation of the FADD-RIPK1-
caspase-8 complex may be context-dependent. In the case of HoipΔhep livers, the 
FADD-RIPK1-caspase-8 complex formation was not inhibited by the allosteric RIPK1 
kinase inhibitor Nec-1s, which suggested that activation of RIPK1 is not required for 
it, or that RIPK1 activation may have already taken place at the time of the treatment, 
which rendered the inhibitor unable to inhibit the complex formation. Also, in this 
thesis, it is not addressed whether RIPK1 inhibition interferes with other processes of 
liver pathogenesis. To answer this question, RIPK1 inhibition in HoipΔhep mice needs 
to be performed in vivo, either by treatment with RIPK1 inhibitor or by crossing those 
mice with RIPK1 kinase-inactive mice. 
RIPK1 is one of the prominent targets of linear ubiquitination in the TNF-RSC, where 
RIPK1 is ubiquitinated by cIAP1/2 and LUBAC in a Lys63-linked and Met1-linked 
manner, respectively (Haas et al., 2009; Gerlach et al., 2011; Draber et al., 2015). 
RIPK1 is also linearly ubiquitinated in the necrosome upon TNF/SM/zVAD 
stimulation (de Almagro et al., 2015). However, it is unclear whether ubiquitination of 
RIPK1 occurs at the TNFR1 signalling, in cytosolic compartments before the 
necrosome formation, or after it. HOIP silencing did not affect TNF/SM/zVAD-
induced necrosome formation or cell death (de Almagro et al., 2015), which implies 
linear ubiquitination is dispensable for necrosome formation and function upon 
TNF/SM/zVAD stimulation. This research claimed that LUBAC can ubiquitinate 
RIPK1 in necrosome in SM-treated cells, where cIAP1 is absent but cIAP2 may still 
be present (de Almagro et al., 2015). In multiple immune signalling pathways, linear 
104 
 
ubiquitin is conjugated to Lys63-linked ubiquitin chains, but not directly on its 
substrates (Emmerich et al., 2013; Emmerich et al., 2016). Also, cIAP1/2 are often 
required for the recruitment of LUBAC to receptor signalling complexes, such as 
those of TNF, CD40 and TCR. In HOIP-deficient livers, RIPK1 is ubiquitinated, 
particularly the fraction recruited to FADD-caspase-8-c-FLIP complex. It is not known 
with which ubiquitin linkage types RIPK1 is modified in the complex. Of note, linear 
ubiquitin was not detected in the complex in both HOIP-proficient and -deficient 
hepatocytes. Therefore it is possible that linear ubiquitination of RIPK1 is essential 
for prevention of the FADD-RIPK1-caspase-8 complex, and thereby protection of 
hepatocytes against apoptosis.  
4.4.2 cIAP1/2 
Loss of IAP proteins triggered by SM induces the formation of a large protein 
complex consisting of RIPK1, FADD, caspase-8/10 and c-FLIP, named ripoptosome, 
formed independently of TNF, TRAIL and CD95L (Tenev et al., 2011; Feoktistova et 
al., 2011). Importantly, ripoptosome formation is reminiscnent of the complex formed 
upon HOIP deficiency in hepatocytes. However, basal IAP loss was not detected in 
HOIP-deficient hepatocytes, unlike NEMO deficiency where it reduces the levels of 
cIAP1/2 (Kondylis et al., 2015). It is not entirely clear how NEMO ablation impairs the 
expression levels of cIAP1/2, but it was suggested that loss of NF-κB signalling could 
be the cause of their downregulation. Although HOIP deficiency in hepatocytes also 
results in lowered canonical NF-κB signalling, at least in response to exogenous TNF, 
it does not seem to affect cIAP levels in the basal condition. Whilst NEMO deficiency 
completely abrogates canonical NF-κB signalling, there seems to be a little residual 
canonical NF-κB activation in the absence of HOIP, which could suffice to maintain 
the 'safe' expression levels of cIAP1/2. However, when HOIP-deficient primary 
hepatocytes were treated with caspase inhibitor zVAD, the levels of cIAP1/2 were 
reduced as compared to HOIP-proficient cells (Figure 3.24).  Thus, there may be a 
mechanism to regulate cIAP1/2 expression in a caspase activity-dependent manner. 
In response to TNF, cIAP1 depletion by treatment with SM is sufficient to induce 
FADD-RIPK1-caspase-8 complex in the presence of LUBAC in the cytosol (Tenev et 
al., 2011; Feoktistova et al., 2011). In TNFR1 signalling, and also in CD40 and TCR 
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signalling, cIAP1/2 are recruited prior to LUBAC to these receptor signalling 
complexes, and cIAP ablation by treatment with SM prevents LUBAC recruitment. It 
is not yet clear whether the increased FADD-RIPK1-caspase-8 formation upon IAP 
loss is dependent on the defect in LUBAC recruitment. To evaluate cIAP1/2's role in 
inhibition of apoptosis in hepatocytes, immunoprecipitation against FADD could be 
performed with lysates of cells treated with SM or knockdown of cIAP1/2. It is an 
interesting question to ask whether or not cIAP1/2 have an additional contribution in 
suppressing apoptosis, as compared to HOIP. 
4.4.3 Necroptosis  
In human NASH patients, RIPK3 is overexpressed in hepatocytes (Gautheron et al., 
2014). In mouse NASH model employing methionine-choline-deficient diet (MCD) or 
in Tak1LPC-KO mice, RIPK3 mediates liver damage, hepatocyte growth and liver 
inflammation in the absence of caspase-8 (Vucur et al., 2013; Gautheron et al., 
2014). These processes require the JNK pathway. However, it is not unequivocal 
whether these functions of RIPK3 are dependent on necroptotic regulation, as RIPK3 
has other functions such as regualtion of inflammasome activation (Kang et al., 
2013). It will be intriguing to know whether MLKL ablation has the same effect as 
RIPK3 deficiency in MCD model and Tak1LPC-KO mice.  
Recent reports suggest that necroptotic cells are immunogenic. Vaccination of 
necroptotic tumour cells into the flank of mice is sufficient to induce antitumour 
immunity and reject tumour cells (Aaes et al., 2016). Necroptotic cells are capable of 
activating CD8+ T cells via cross-presentation by DCs. Necroptosis induces DC 
activation and cross-priming of CD8+ T cells more efficiently than apoptotic cells 
(Yatim et al., 2015). RIPK3 oligomerisation via RHIM domains leads to RIPK1-
dependent NF-κB-mediated gene activation and the immunogenicity of necroptotic 
cell death requires NF-κB signalling (Yatim et al., 2015). Therefore, if there are 
necroptotic cells in the liver, they could amplify the inflammation. 
Caspase-8 deletion in parenchyma leads to mild necrosis in the liver (Vucur et al., 
2013). This is in contrast with the severe phenotype of caspase-8 ablation in the skin 
and intestinal epithelium, where it leads to dermatitis and ileitis, respectively, driven 
by RIPK3-mediated necroptosis (Kovalenko et al., 2009; Gunther et al., 2011; 
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Weinlich et al., 2013).  Moreover, RIPK1 deletion leads to uncontrolled RIPK3 
activation in a kinase-independent fashion (Dannappel et al., 2014; Dillon et al., 
2014; Rickard et al., 2014). Thus, deregulation of TNFR1 signalling by LUBAC 
deficiency could promote necroptosis. Indeed, the skin in cpdm mice bears 
necroptotic cells as evaluated by phospho-MLKL staining and electron microscopy 
(Shimizu et al., 2016). 
Currently, there is no decisive marker for necroptotic death in the field, although 
some scientists adopted phosphorylation of MLKL as a necroptosis marker (Wang et 
al., 2014; Shimizu et al., 2016). Necroptotic cells can be TUNEL-negative as some 
reports highlighted the features of necroptotic death. For instance, cells infected with 
Shigella die by necroptosis, where cells are negative for TUNEL (Carneiro et al., 
2009). Thus, it is possible that TUNEL staining did not fully detect necroptosis in 
HoipΔhep livers. 
Yet in HOIP-deficient liver and hepatocytes, phosphorylation of MLKL was not 
detected in the lysates. This does not exclude the possibility of necroptosis in HOIP-
deficient livers. Yet, considering that substantial activation of caspase-8 is seen in 
HOIP-deficient hepatocytes, caspase-8 is most likely active enough to prevent 
RIPK1 and RIPK3 from executing necroptosis. MLKL is currently considered to 
execute necroptosis downstream of RIPK3 (Peltzer et al., 2014; Conrad et al., 2016). 
Moreover, the locus of Ripk3 gene is in the proximity of Hoip gene, which does not 
allow us to create RIPK3-deficient HOIP-floxed mice by mating the two strains. Thus, 
instead of RIPK3 deficiency, MLKL knockout mice was employed in this study. MLKL 
deletion in Casp8HET HoipΔhep did not ameliorate liver injury, indicating that MLKL-
mediated necroptosis is unlikely to be a major player in the pathogenesis of HoipΔhep 
livers. 
4.4.4 LUBAC substrates 
Aside from RIPK1, the known substrates of LUBAC in TNFR1 signalling are TNFR1, 
TRADD and NEMO (Gerlach et al., 2011; Draber et al., 2015). Because caspase-8 
activation in HOIP-deficient hepatocytes is independent of TNFR1, ubiquitination of 
TNFR1 is highly unlikely to be involved in the cell death induction. Secondly, TRADD 
can be a part of cell death-inducing complex in TNF signalling when gene activation 
107 
 
is impaired or in the absence of RIPK1 (Figure 1.4). TRADD contributes to the 'slow' 
apoptotic process as compared to FADD-RIPK1-caspase-8, which mediates 'fast' 
apoptosis in NemoLPC-KO livers when RIPK1 is absent (Kondylis et al., 2015). In 
HOIP-deficient hepatocytes, TRADD was not detected in the FADD-associated 
complex although the band of TRADD could have been overshadowed by an intense 
signal of the immunoglobulin derived from anti-FADD antibody used in 
immunoprecipitation, due to their proximity in the molecular size. Although the role of 
linear ubiquitination on TRADD is entirely unknown at present, in the absence of 
LUBAC, TRADD might mediate apoptotic signalling. 
NEMO is not only a linear ubiquitin binding protein but also the first-described 
substrate for LUBAC (Tokunaga et al., 2009; Gerlach et al., 2011). NEMO 
ubiquitination is described to be required for activation of canonical NF-κB pathway 
(Tokunaga et al., 2009; Jun et al., 2013). It is still unclear whether NEMO 
ubiquitination, in contrast to ubiquitin binding via its UBAN domain, is required for 
inhibition of apoptosis. 
Ikeda and colleagues reported at a conference that FADD can be linearly 
ubiquitinated in TNFR1 signalling (Ikeda, European Workshop of Cell Death, 2014), 
primarily based on in-vitro ubiquitination studies. FADD ubiquitination in the FADD-
RIPK1-caspase-8 complex was not detected in HOIP-deficient hepatocytes. FADD 
appears to be the core component of the caspase-8 activating complex in HOIP-
deficient hepatocytes. NEMO-deficient hepatocytes undergo apoptosis by activating 
caspase-8 via FADD, as FADD deletion significantly reduced their apoptosis, where 
FADD plays a central role in their cell death by forming the FADD-RIPK1-caspase-8 
complex (Luedde et al., 2007; Kondylis et al., 2015). Thus, it may be hypothesised 
that concomitant FADD deletion could abolish caspase-8 activation and, hence, 
apoptosis of HOIP-deficient hepatocytes. 
4.4.5 LUBAC and linear chain associated proteins 
LUBAC is constitutively associated with two DUBs, OTULIN and CYLD. These DUBs 
are associated with HOIP in two distinct pools (Draber et al., 2015; Hrdinka et al., 
2016). While the recruitment of OTULIN to TNFR1 or NOD2 signalling complex is 
controversial, CYLD is recruited to these receptor complexes, depending on HOIP's 
108 
 
presence but independently of HOIP’s catalytic activity (Draber et al., 2015). In 
addition to the role as a suppressor of NF-κB signalling, CYLD promotes necrosome 
formation by cleaving ubiquitin chains on RIPK1 and thereby necroptosis (O'Donnell 
et al., 2011; Moquin et al., 2013).  
HOIP deficiency might affect CYLD’s function, its proper recruitment and/or 
intracellular localisation. As CYLD truncation in the liver leads to hepatocyte 
apoptosis (Nikolaou et al., 2012), which is akin to the phenotype of HOIP deficiency, 
the pro-apoptotic effect of LUBAC deficiency in hepatocytes might be attributable to 
deregulation of CYLD. It has been shown that SPATA2 mediates binding between 
HOIP and CYLD, and regulates NF-κB activation and TNF-induced necroptosis 
(Wagner et al., 2016; Kupka et al., in press). However, at the moment it is completely 
unknown whether this function of SPATA2 on signalling and cell death is entirely 
dependent on its binding to CYLD. 
A20 recruitment to the TNF-RSC is dependent on the binding to linear ubiquitin and 
HOIP’s catalytic activity (Tokunaga et al., 2013; Draber et al., 2015).  A20 serves as 
an inhibitor of TNF-induced apoptosis (Lee et al., 2000). Particularly mutation of ZF7 
of A20, which lacks its binding site to linear ubiquitin, sensitises cells to TNF-induced 
cell death (Draber et al., 2015; Yamaguchi et al., 2015).  Although A20 deletion in 
LPCs does not trigger spontaneous liver damage, A20LPC-KO mice are more sensitive 
to TNF-induced hepatitis, which is dependent on FADD-mediated apoptosis 
(Catrysse et al., 2016). Also, A20 counteracts NASH by attenuating accumulation of 
fatty acids in hepatocytes (Ai et al., 2015). Thus, loss of HOIP could disrupt A20 
recruitment to signalling complexes which are mediated by linear ubiquitination, and 
increase susceptibility to cell death and fat deposition.  
NEMO recruitment to the TNF-RSC is also LUBAC-dependent (Haas et al., 2009). 
NEMO deficiency in LPCs leads to much more severe pathology in the liver, as 
compared to HoipΔhep. Therefore it is unlikely that LUBAC deficiency results in 
complete loss of function of NEMO. Nevertheless, some of the functions of NEMO 
might be impaired by LUBAC deficiency because NEMO may not be properly 
recruited to certain complexes. In addition to A20 and NEMO, functions of other 
linear ubiquitin binding proteins might be disrupted by LUBAC deficiency in 
hepatocytes. For instance, the recruitment of UBAN-carrying protein ABIN-1 could 
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be impaired as well. ABIN-1 inhibits FADD-caspase-8 association and protects 
hepatocytes from TNF-induced cell death depending on the presence of the UBAN 
domain (Oshima et al., 2009).   
Taken together, HOIP abrogation could promote cell death via mislocating LUBAC- 
and linear ubiquitin-associated factors. It will be tempting to dissect the catalytic 
activity and the scaffolding function of HOIP in the liver pathogenesis by employing 
the catalytically inactive mutant of HOIP. Inactive HOIP mutant abrogates linear 
polyubiquitin production and would affect proper localisation of linear ubiquitin 
binding proteins in the signalling as previously shown in TNF signalling, while 
maintaining the recruitment of LUBAC-associated proteins such as SPATA2-CYLD 
and/or OTULIN intact (Figure 4.2).  
 
 
Figure 4.2 Schematic of the potential consequences of HOIP inactivation. Inactivation of HOIP 
leads to the loss of linear ubiquitin linkage on its substrates. This impairs the recruitment of complex 
components; for instance, linear ubiquitin receptors are not recruited to LUBAC substrates in the 
corresponding signalling complexes, which would cause sub-optimal activation of signalling and 




4.5 Summary and outlook  
In this thesis, the role of LUBAC deficiency on liver homeostasis and the molecular 
mechanisms thereof has been investigated. LUBAC protects hepatocytes against 
apoptosis via preventing FADD-RIPK1-caspase-8 cell death-inducing complex. In 
addition, LUBAC positively regulates canonical NF-κB signalling. These pro-survival 
functions of LUBAC are abrogated by HOIP depletion, resulting in hepatocyte 
apoptosis and liver inflammation. Liver inflammation is a crucial incident to create a 
pro-tumourigenic environment by initiation of the regenerative process and induction 
of DNA damage (Figure 4.3).  
 
Figure 4.3 Schematic representation of the molecular function of HOIP in hepatocytes 
 
Interestingly, the first aberrant event in HOIP-deficient livers is cell death, which is 
independent of the TNFR1 presence in hepatocytes. By contrast, the following 
events, inflammation and DNA damage response require TNFR1 signalling. These 
results indicate that there is a clear distinction of regulation between cell death and 
inflammation in the liver.   
Previous studies strongly suggested that liver inflammation due to disruption of NF-
κB signalling is driven by apoptotic signalling (Vucur et al., 2013; Kondylis et al., 
2015). In our mouse model of LUBAC deficiency, it is not entirely clear yet if 
caspase-8 deletion together with MLKL deletion results in a complete rescue of 
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inflammation and carcinogenesis, which requires further clarification. The obstacle 
for examining MlklKO Casp8HET HoipΔhep mice is their early development of 
lymphadenopathy around 2-3 months of age. To circumvent this problem, 
hematopoietic cells in MlklKO Casp8KO HoipΔhep mice could be reconstituted with 
MlklKO Casp8HET or wild-type bone marrow cells after irradiation. Alternatively, it is 
possible to employ caspase-8 floxed strain, instead of systemic caspase-8 knockout 
mice, to avoid its deletion in non-LPCs, particularly in the immune system. 
The precise mechanism of caspase-8 activation in HOIP-deficient hepatocytes 
remains still elusive. How is the FADD-RIPK1-caspase-8 complex formed in HOIP-
deficient hepatocytes? Does this require some exogenous stimuli? Or the mere 
LUBAC deficiency is sufficient to trigger this? The potential involvement of some 
death receptor signalling can be tested by employing, for instance, TRAIL-R and 
CD95 knockout animals. TLR signalling can be evaluated by crossing with MyD88 
knockout mice except for TLR3 signalling, which can be addressed by TLR3 or TRIF 
deficiency.  
Furthermore, how LUBAC is involved in the prevention of the complex formation is 
still a conundrum. Is linear ubiquitination of the complex component(s) sufficient for 
the inhibition, or is the scaffolding function of HOIP, for instance binding to OTULIN 
and/or SPATA2-CYLD complex, required for it? To answer these questions, a further 
dissection of the functions of HOIP would be essential. If the loss of linear 
ubiquitination is solely accountable for the phenotype, there must be one or multiple 
LUBAC substrates that is linearly ubiquitinated in hepatocytes under steady state 
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